Vinayak Prasad, MD, MPH

Title(s)Professor, Epidemiology & Biostatistics
SchoolSchool of Medicine
Address550 16th Street, #2549
San Francisco CA 94158
Phone--
ORCID ORCID Icon0000-0002-6110-8221 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of ChicagoMDMedicine

    Collapse Overview 
    Collapse Overview
    Vinay Prasad MD MPH is Professor of Epidemiology and Biostatistics and Medicine, and a practicing Hematologist Oncologist at San Francisco General Hospital. Dr. Prasad cares for patients with a wide range of medical concerns, including classic hematology, malignant hematology, and solid tumors. He conducts research at the intersection of health policy, evidence based medicine and oncology.

    Dr. Prasad trained at the University of Chicago, Pritzker School of Medicine, where he was recipient of the Chairman's Award in Internal Medicine, given to the graduate with highest marks in Internal Medicine and its subspecialties. He finished residency in Internal Medicine at Northwestern University, where he won the Gerald Grumet Award for best resident teacher. He completed fellowship at the National Cancer Institute and National Institutes of Health in Hematology and Medical Oncology, where he was Chief Fellow, and a Cancer Prevention Fellow.

    Dr. Prasad completed his Masters in Public Health from Johns Hopkins University. For 5 years, Dr. Prasad was Assistant and then Associate Professor at the Oregon Health and Science University, where he won 4 teaching awards in consecutive years (2017-20), including the J David Bristow Award, given by the graduating medical school class to "a faculty member who exemplifies the ideals of the true physician as he or she conducts clinical practice with patients and colleagues," and the Craig Okada award for best teacher in the hematology oncology fellowship program. Dr Prasad moved to UCSF in 2020. In 2022, he won the Excellence in Teaching Award at UCSF, and in 2023, he received the Distinguished Contribution to Teaching Award also at UCSF.

    Dr. Prasad studies medical evidence, clinical decision making, health policy, and cancer drug pricing. With Adam Cifu, he coined the term Medical Reversal-- a phenomenon where medical practice flip flops, and published several papers defining its scope and impact. His work on cancer drug policy has defined the appropriate role of surrogate endpoints, and probed issues of cost and value.

    He is the author of over 400 peer reviewed papers, including articles in the New England Journal of Medicine, JAMA, BMJ, Nature, the Annals of Internal Medicine and JAMA Internal Medicine. He has also written 2 peer reviewed books, published by Johns Hopkins University Press: Ending Medical Reversal and Malignant. He hosts the podcast Plenary Session, which is the #1 oncology podcast globally by downloads, and the VPZD show, a general interest science show. He is active on Youtube and Substack. On Youtube, the channel Vinay Prasad MD MPH has over 100,000 subscribers. On Substack, Dr Prasad writes Vinay Prasad's Observations and Thoughts, and co-writers Sensible Medicine.

    Dr Prasad is the author of over 100 op-eds in media outlets including the New York Times, the Washington Post, STAT, US News and World Report, and many other outlets. He has been the guest on numerous podcasts including Honestly, Breaking Points and EconTalk. He runs the research lab www.vkprasadlab.com, and has supervised over 100 trainees on research papers.

    You can learn more about his work on www.vinayakkprasad.com and https://www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

    Collapse Research 
    Collapse Research Activities and Funding
    Low and No Value Care
    Arnold Ventures

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Collaboration Interests
    Collapse Faculty Mentoring
    Collapse Global Health

    Collapse Featured Content 
    Collapse Twitter
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities. J Med Ethics. 2024 Jan 23; 50(2):126-138. Bardosh K, Krug A, Jamrozik E, Lemmens T, Keshavjee S, Prasad V, Makary MA, Baral S, Høeg TB. PMID: 36600579.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    2. Sotorasib in KRASG12C mutated lung cancer. Lancet. 2024 Jan 13; 403(10422):145. Olivier T, Prasad V. PMID: 38218611.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. T-Cell Lymphoma From CAR T-Cell Therapy-A New Safety Notice. JAMA. 2024 Jan 11. Prasad V. PMID: 38206604.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Concerns That May Limit the Utility of Zuranolone. JAMA. 2024 Jan 09; 331(2):105-106. Prasad V, Allely D. PMID: 38100400.
      View in: PubMed   Mentions:    Fields:    
    5. Discrepancies in Estimating Excess Death by Political Party Affiliation During the COVID-19 Pandemic. JAMA Intern Med. 2024 Jan 01; 184(1):118-119. Dasaro C, Haslam A, Prasad V. PMID: 38010692.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    6. The Ethical Obligation for Research During Public Health Emergencies: Insights From the COVID-19 Pandemic. Med Health Care Philos. 2023 Dec 28. Barosa M, Jamrozik E, Prasad V. PMID: 38153559.
      View in: PubMed   Mentions:    Fields:    
    7. Assessing patient burden and benefit: A decade of cabozantinib clinical trials. Int J Cancer. 2023 Dec 18. Hughes GK, Sajjadi NB, Gardner B, Ramoin JK, Tuia J, Haslam A, Prasad V, Vassar M. PMID: 38108216.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Reliance on the highest-quality studies of Long Covid is appropriate and not evidence of bias. BMJ Evid Based Med. 2023 Dec 07. Høeg TB, Ladhani S, Prasad V. PMID: 38071561.
      View in: PubMed   Mentions:    Fields:    
    9. Characteristics and outcomes of new molecular oncology drug approvals, in combination or monotherapy. J Cancer Policy. 2023 Dec 05; 39:100462. Ranganathan S, Haslam A, Tuia J, Prasad V. PMID: 38061492.
      View in: PubMed   Mentions:    Fields:    
    10. Cancer Drug Price and Novelty in Mechanism of Action. JAMA Netw Open. 2023 Dec 01; 6(12):e2347006. Miljkovic MD, Tuia J, Olivier T, Haslam A, Prasad V. PMID: 38079171; PMCID: PMC10714245.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Estimation of eligibility for and response to CAR-T therapy in the United States. Blood Adv. 2023 Dec 01. Haslam A, Høeg TB, Prasad V. PMID: 38039516.
      View in: PubMed   Mentions:    Fields:    
    12. Rapid antigen testing for COVID-19: Decreasing diagnostic reliability, potential detrimental effects and a lack of evidence to support continued public funding of community-based testing. Public Health Pract (Oxf). 2023 Dec; 6:100451. Høeg TB, Prasad V. PMID: 38075468; PMCID: PMC10701347.
      View in: PubMed   Mentions:
    13. Starting and stopping cancer drugs: The need for randomized trials. J Cancer Policy. 2023 Dec; 38:100451. Benjamin DJ, Prasad V. PMID: 37918654.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Systematic Review and Meta-Analysis of Randomized Trials Testing Interventions to Reduce Physician Burnout. Am J Med. 2023 Oct 25. Haslam A, Tuia J, Miller SL, Prasad V. PMID: 37890569.
      View in: PubMed   Mentions:    Fields:    
    15. Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed. Nat Rev Clin Oncol. 2023 Dec; 20(12):885-895. Walia A, Tuia J, Prasad V. PMID: 37828154.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    16. Eligibility for Human Leukocyte Antigen-Based Therapeutics by Race and Ethnicity. JAMA Netw Open. 2023 10 02; 6(10):e2338612. Olivier T, Haslam A, Tuia J, Prasad V. PMID: 37883087; PMCID: PMC10603498.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. An Analysis of Studies Pertaining to Masks in Morbidity and Mortality Weekly Report: Characteristics and Quality of Studies through 2023. Am J Med. 2024 Feb; 137(2):154-162.e1. Høeg TB, Haslam A, Prasad V. PMID: 37777144.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. How methodological pitfalls have created widespread misunderstanding about long COVID. BMJ Evid Based Med. 2023 Sep 25. Høeg TB, Ladhani S, Prasad V. PMID: 37748921.
      View in: PubMed   Mentions: 1     Fields:    
    19. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023 Sep 14; 389(11):1052-1053. Allely D, Prasad V. PMID: 37703561.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Flu advice in the U.S. news media changed during the COVID-19 pandemic but not the evidence. Eur J Epidemiol. 2023 Oct; 38(10):1115-1117. Brown E, Haslam A, Prasad V. PMID: 37697025.
      View in: PubMed   Mentions:    Fields:    
    21. Does equipoise exist for masking children for COVID-19? Public Health Pract (Oxf). 2023 Dec; 6:100428. Høeg TB, González-Dambrauskas S, Prasad V. PMID: 37744300; PMCID: PMC10511791.
      View in: PubMed   Mentions: 1  
    22. Reevaluating Adjuvant Capecitabine for Resected Biliary Tract Cancer. Oncologist. 2023 Sep 08. Benjamin DJ, Prasad V. PMID: 37682029.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    23. Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer. BMC Med. 2023 09 08; 21(1):344. Olivier T, Haslam A, Prasad V. PMID: 37679732; PMCID: PMC10485976.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Cost of Drug Wastage From Dose Modification and Discontinuation of Oral Anticancer Drugs. JAMA Oncol. 2023 09 01; 9(9):1238-1244. Lam M, Olivier T, Haslam A, Tuia J, Prasad V. PMID: 37471095; PMCID: PMC10360002.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Detecting Selection Bias in Observational Studies-When Interventions Work Too Fast. JAMA Intern Med. 2023 09 01; 183(9):897-898. Mohyuddin GR, Prasad V. PMID: 37306983.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Extended anticoagulation for VTE: what evidence justifies it? Front Pharmacol. 2023; 14:1241979. Walia A, Prasad V. PMID: 37711176; PMCID: PMC10497742.
      View in: PubMed   Mentions:
    27. Financial conflicts of interest of physicians followed by oncology journals on Twitter. J Cancer Res Clin Oncol. 2023 Nov; 149(15):14137-14144. Betts C, Kakkilaya A, Vasireddy S, Arora N, Prasad V, Powell K. PMID: 37552310.
      View in: PubMed   Mentions:    Fields:    
    28. Evidence Base for Health Care Strategies to Protect Vulnerable Patients During the COVID-19 Pandemic. JAMA Oncol. 2023 08 01; 9(8):1150. Haslam A, Prasad V. PMID: 37261802.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    29. Potential "Healthy Vaccinee Bias" in a Study of BNT162b2 Vaccine against Covid-19. N Engl J Med. 2023 Jul 20; 389(3):284-285. Høeg TB, Duriseti R, Prasad V. PMID: 37470285.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. Multiple myeloma: challenges with deciding the optimal sequencing strategy. Front Pharmacol. 2023; 14:1231720. Walia A, Haslam A, Tuia J, Prasad V. PMID: 37465528; PMCID: PMC10350499.
      View in: PubMed   Mentions:
    31. Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use. Trials. 2023 Jun 03; 24(1):373. Prasad V, Kim MS, Haslam A. PMID: 37270500; PMCID: PMC10239129.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    32. Quality of life in the adjuvant setting: A meta-analysis of US Food and Drug Administration approved anti-cancer drugs from 2018 to 2022. J Cancer Policy. 2023 09; 37:100426. Olivier T, Smith CEP, Haslam A, Addeo A, Prasad V. PMID: 37270063.
      View in: PubMed   Mentions:    Fields:    
    33. Scoping Review of Published Oncology Meta-analyses in High-Impact Oncology Journals. JAMA Netw Open. 2023 06 01; 6(6):e2318877. Haslam A, Tuia J, Prasad V. PMID: 37358855; PMCID: PMC10293908.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. University-age vaccine mandates: reply to Lam and Nichols. J Med Ethics. 2023 May 24. Høeg TB, Krug A, Baral S, Jamrozik E, Keshavjee S, Lemmens T, Prasad V, Makary MA, Bardosh K. PMID: 37225414.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    35. Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020. BMC Cancer. 2023 May 17; 23(1):448. Olivier T, Haslam A, Prasad V. PMID: 37198564; PMCID: PMC10189952.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    36. Profile of the Oncology Physician Workforce and the Characteristics of Attrition. JCO Oncol Pract. 2023 07; 19(7):465-472. Tuia J, Haslam A, Prasad V. PMID: 37186885.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    37. Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC. J Cancer Res Clin Oncol. 2023 Sep; 149(11):9513-9515. Walia A, Prasad V. PMID: 37178425; PMCID: PMC10374679.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. PARP inhibitors and overall survival in ovarian cancer, reevaluation advised in all settings. J Cancer Res Clin Oncol. 2023 Sep; 149(11):9509-9512. Olivier T, Prasad V. PMID: 37162545.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    39. Cross-sectional analysis of open payments for physicians at designated hemophilia centers in the US (2018-2020). Thromb Res. 2023 07; 227:40-44. Haslam A, Prasad V. PMID: 37210957.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    40. Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-analysis. JAMA Intern Med. 2023 05 01; 183(5):435-441. Banerjee T, Kim MS, Haslam A, Prasad V. PMID: 36939665; PMCID: PMC10028543.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    41. The United States' decision to mask children as young as two for COVID-19 has been extended into 2023 and beyond: The implications of this policy. Paediatr Respir Rev. 2023 09; 47:30-32. Høeg TB, González-Dambrauskas S, Prasad V. PMID: 37183122; PMCID: PMC10129335.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    42. Is financial toxicity captured in quality of life assessments in oncology randomized clinical trials? J Cancer Policy. 2023 06; 36:100423. Olivier T, Haslam A, Prasad V. PMID: 37075841.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    43. The definition of long COVID used in interventional studies. Eur J Clin Invest. 2023 Aug; 53(8):e13989. Haslam A, Olivier T, Prasad V. PMID: 36964995.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    44. Unknown Causes of Death in Cancer Patients. Am J Clin Oncol. 2023 06 01; 46(6):246-253. Chinniah S, Chiam M, Mani K, Liang M, Trifiletti DM, Spratt DE, Prasad VK, Wang M, Tchelebi LT, Zaorsky NG. PMID: 37038261.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. Chaotic advection in a recirculating flow: Effect of a fluid multiple-flexible-solid interaction. Chaos. 2023 Apr 01; 33(4). Prasad V, Sharma A, Kulkarni SS. PMID: 37097943.
      View in: PubMed   Mentions:    Fields:    
    46. Omission of Critical Information From Clinical Trial Reports-What to Do About Uninterpretable Results. JAMA Oncol. 2023 04 01; 9(4):459-460. Olivier T, Haslam A, Prasad V. PMID: 36821106.
      View in: PubMed   Mentions:    Fields:    
    47. The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review. J Cancer Res Clin Oncol. 2023 Aug; 149(10):7355-7362. Bhatt A, Haslam A, Prasad V. PMID: 36928160; PMCID: PMC10374733.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    48. Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm. Blood Cancer J. 2023 03 15; 13(1):36. Walia A, Prasad V. PMID: 36918528; PMCID: PMC10015061.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    49. An evidence double standard for pharmacological versus non-pharmacological interventions: Lessons from the COVID-19 pandemic. Contemp Clin Trials Commun. 2023 Jun; 33:101108. Høeg TB, Prasad VK. PMID: 36938319; PMCID: PMC10008034.
      View in: PubMed   Mentions:
    50. CME: Is it Meeting the Mark? Am J Med. 2023 07; 136(7):618-619. Ranganathan S, Prasad V. PMID: 36898599.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    51. The Reply. Am J Med. 2023 Mar; 136(3):e48. Olivier T, Gill J, Prasad V. PMID: 36796954.
      View in: PubMed   Mentions:    Fields:    
    52. Visualizing the randomized sham-controlled trial in orthopedic research: proposed steps to conducting a total knee arthroplasty randomized controlled trial. J Comp Eff Res. 2023 03; 12(3):e210275. Tran AA, Prasad V. PMID: 36847310; PMCID: PMC10288945.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    53. The response rate by tumour type for tissue-agnostic approved drugs. Eur J Cancer. 2023 05; 184:117-119. Haslam A, Prasad V. PMID: 36913833.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    54. Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer. Eur Urol. 2023 06; 83(6):584-585. Olivier T, Tsantoulis P, Prasad V. PMID: 36781336.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    55. Quality of content reporting on two major oncology media websites: OncLive and Targeted Oncology. J Cancer Policy. 2023 06; 36:100411. Sharma N, Wayant C, Neupane K, Lenka J, Berger K, Goodman AM, Booth CM, Prasad V, Mohyuddin GR. PMID: 36773798.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    56. Prostate-specific Membrane Antigen Positron Emission Tomography in the Staging of Newly Diagnosed Prostate Cancer: Is More Sensitivity Always Better? Eur Urol. 2023 06; 83(6):481-483. Varatharajan A, Olivier T, Prasad V. PMID: 36774222.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    57. Is it time to reconsider molecular response milestones in chronic myeloid leukemia? Am J Hematol. 2023 04; 98(4):562-563. Walia A, Prasad V. PMID: 36708357.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    58. Interpreting the results from the first randomised controlled trial of colonoscopy: does it save lives? BMJ Evid Based Med. 2023 10; 28(5):306-308. Powell K, Prasad V. PMID: 36754585; PMCID: PMC10579474.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    59. Front-line chronic lymphocytic leukemia: The role of chemoimmunotherapy. Am J Hematol. 2023 04; 98(4):560-561. Kim MS, Prasad V. PMID: 36701133.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    60. Frequency and Characteristics of Trials Using Medical Writer Support in High-Impact Oncology Journals. JAMA Netw Open. 2023 02 01; 6(2):e2254405. Buck E, Haslam A, Tuia J, Prasad V. PMID: 36723940; PMCID: PMC9892954.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    61. Comparability of Control and Comparison Groups in Studies Assessing Long COVID. Am J Med. 2023 Jan 25. Haslam A, Prasad V. PMID: 36708796; PMCID: PMC9912142.
      View in: PubMed   Mentions: 2     Fields:    
    62. Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers. BMC Cancer. 2023 Jan 13; 23(1):46. Haslam A, Olivier T, Tuia J, Prasad V. PMID: 36639625.
      View in: PubMed   Mentions: 3     Fields:    
    63. Adjuvant checkpoint inhibitor trials: Is disease-free survival an appropriate endpoint? J Cancer Policy. 2023 03; 35:100402. Khaki AR, Lythgoe MP, Prasad V. PMID: 36639103.
      View in: PubMed   Mentions:    Fields:    
    64. The role of surgery in metastatic cancer: the case for a pragmatic tumor-agnostic randomized trial. Future Oncol. 2022 11; 18(36):3955-3959. Powell K, Marquart J, Olivier T, Prasad V. PMID: 36621818.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    65. Paxlovid: A Regulatory Gamble. Am J Med. 2023 04; 136(4):336-338. Miljkovic MD, Prasad V. PMID: 36608747.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    66. Financial conflicts of interest of physicians followed by neurosurgical journals on Twitter. Int J Health Plann Manage. 2023 May; 38(3):679-686. Powell K, McCall K, Hooda K, Prasad V, Kakkilaya A. PMID: 36597174.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    67. COVID-19 vaccine induced myocarditis in young males: A systematic review. Eur J Clin Invest. 2023 Apr; 53(4):e13947. Knudsen B, Prasad V. PMID: 36576362; PMCID: PMC9880674.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    68. Sotorasib in KRASG12C mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival? Transl Oncol. 2022 Dec 26; 28:101591. Olivier T, Haslam A, Prasad V. PMID: 36577165.
      View in: PubMed   Mentions: 1  
    69. A novel trial methodology to test interventions with very large effect sizes: the case of dostarlimab in mismatch repair-deficient, locally advanced rectal cancer. Trials. 2022 Dec 24; 23(1):1044. Powell K, Olivier T, Prasad V. PMID: 36564825.
      View in: PubMed   Mentions: 1     Fields:    
    70. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol. 2023 03; 200(5):587-594. Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR. PMID: 36495317.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    71. Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020. JAMA Intern Med. 2022 Dec 01; 182(12):1319-1320. Miljkovic MD, Tuia JE, Olivier T, Haslam A, Prasad V. PMID: 36315136; PMCID: PMC9623474.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    72. Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020. Blood Cancer J. 2022 11 15; 12(11):155. Van Oekelen O, Birrer N, Wesson W, Galate VL, Cliff ERS, Goodman AM, Abdallah AO, Chakraborty R, Prasad V, Mohyuddin GR. PMID: 36379917; PMCID: PMC9666639.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    73. Financial conflicts of interest of OncoAlert: An informal oncology professional network. J Cancer Policy. 2022 Dec; 34:100369. Powell K, Kakkilaya A, Haslam A, Prasad V. PMID: 36396090.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    74. Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment. BMC Med. 2022 11 09; 20(1):392. Olivier T, Prasad V. PMID: 36348413; PMCID: PMC9644653.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    75. A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target. Eur J Cancer. 2023 01; 178:227-233. Haslam A, Olivier T, Tuia J, Prasad V. PMID: 36493558.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    76. Pembrolizumab for all. J Cancer Res Clin Oncol. 2023 Mar; 149(3):1357-1360. Kim MS, Prasad V. PMID: 36271954; PMCID: PMC9984312.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    77. Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. N Engl J Med. 2022 10 20; 387(16):1527. Haslam A, Prasad V. PMID: 36260800.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    78. What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020). BMJ Open. 2022 10 07; 12(10):e064458. Jenei K, Haslam A, Olivier T, Miljkovíc M, Prasad V. PMID: 36207035; PMCID: PMC9558788.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    79. Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: A cross sectional analysis. J Cancer Policy. 2022 Dec; 34:100363. Prasad V, Olivier T, Chen EY, Haslam A. PMID: 36162749.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    80. FDA validation of surrogate endpoints in oncology: 2005-2022. J Cancer Policy. 2022 Dec; 34:100364. Walia A, Haslam A, Prasad V. PMID: 36155118.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    81. Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint. Eur Urol. 2023 02; 83(2):101-102. Powell K, Burns MC, Prasad V. PMID: 36153246.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    82. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023 07; 84(1):4-6. Olivier T, Powell K, Prasad V. PMID: 36096857.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    83. Crossover in Adjuvant Trastuzumab Trials: Sparing Toxicity in Patient Care. Am J Clin Oncol. 2022 10 01; 45(10):438-441. Tuia JE, Olivier T, Prasad VK. PMID: 36073967.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    84. The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many? Transl Oncol. 2022 Nov; 25:101523. Bhatt A, Powell K, Prasad V. PMID: 36063621; PMCID: PMC9460510.
      View in: PubMed   Mentions:
    85. Control participants of randomised trials: an often forgotten, vulnerable population. Lancet Haematol. 2022 09; 9(9):e634-e636. Mohyuddin GR, Mehra N, Ryll B, Prasad V. PMID: 36055323.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    86. Characteristics of Facebook's third-party medical fact checkers. Digit Health. 2022 Jan-Dec; 8:20552076221120318. Haslam A, Prasad V. PMID: 36003316; PMCID: PMC9393657.
      View in: PubMed   Mentions:
    87. Neoadjuvant checkpoint inhibition in non-small cell lung cancer: Is earlier unquestionably better than later? Transl Oncol. 2022 Oct; 24:101505. Olivier T, Prasad V. PMID: 35953223; PMCID: PMC9381437.
      View in: PubMed   Mentions:
    88. PI3K inhibitors in haematological malignancies. Lancet Oncol. 2022 08; 23(8):e362-e363. Benjamin DJ, Prasad V. PMID: 35901824.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    89. Constructive and obsessive criticism in science. Eur J Clin Invest. 2022 Nov; 52(11):e13839. Prasad V, Ioannidis JPA. PMID: 35869811; PMCID: PMC9787955.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    90. Common misconceptions of randomized controlled trials in oncology. Eur J Clin Invest. 2022 Nov; 52(11):e13832. Powell K, Prasad V. PMID: 35842736.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    91. Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021. Eur J Cancer. 2022 09; 172:349-356. Olivier T, Haslam A, Prasad V. PMID: 35830842.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    92. CostPlus and implications for generic imatinib. Lancet Reg Health Am. 2022 Sep; 13:100317. Jenei K, Lythgoe MP, Prasad V. PMID: 36777318; PMCID: PMC9903877.
      View in: PubMed   Mentions:
    93. Eventual success rate and predictors of success for oncology drugs tested in phase I trials. Int J Cancer. 2023 01 15; 152(2):276-282. Haslam A, Olivier T, Powell K, Tuia J, Prasad V. PMID: 35716142.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    94. Contact Tracing Policy for Masked Students May be an Important Confounding Variable. Pediatrics. 2022 07 01; 150(1). Høeg TB, Prasad V, Porter T. PMID: 35765968.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    95. Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines. Transl Oncol. 2022 Sep; 23:101475. Olivier T, Prasad V. PMID: 35785671; PMCID: PMC9256830.
      View in: PubMed   Mentions: 5  
    96. Ivosidenib and Azacitidine in IDH1-Mutated AML. N Engl J Med. 2022 06 30; 386(26):2536. Goodman AM, Mohyuddin GR, Prasad V. PMID: 35767449.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    97. Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology. Br J Cancer. 2022 09; 127(5):785-787. Lythgoe MP, Prasad V. PMID: 35739301; PMCID: PMC9427732.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    98. Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials. Blood Adv. 2022 06 14; 6(11):3329-3331. Olivier T, Prasad V, Marini BL. PMID: 35286368; PMCID: PMC9198931.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    99. Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians? JCO Oncol Pract. 2022 07; 18(7):e1164-e1169. Wright K, Meyers DE, Chisamore TM, McInnes MDF, Sismondo S, Gyawali B, Prasad V, Booth CM. PMID: 35696634.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    100. General payments from Biogen to U.S. physicians between 2015 and 2020. J Am Geriatr Soc. 2022 10; 70(10):3035-3038. Jenei K, Lythgoe MP, Prasad V. PMID: 35665914.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    101. Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022. JAMA Netw Open. 2022 06 01; 5(6):e2216058. Mousavi I, Olivier T, Prasad V. PMID: 35687338; PMCID: PMC9187950.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    102. Corrigendum to 'Multi-Cancer Screening Tests: Communicating About Risks Should be Prioritized' AmJMed 2021;135(4):413-415. Am J Med. 2022 Aug; 135(8):1031. Olivier T, Gill J, Prasad V. PMID: 35624051.
      View in: PubMed   Mentions:    Fields:    
    103. Case for investment in tobacco cessation: a population-based analysis in low- and middle-income countries. Rev Panam Salud Publica. 2022; 46:e71. Sandoval GA, Totanes R, David AM, Fu D, Bettcher D, Prasad V, Arnold V. PMID: 36211243; PMCID: PMC9534346.
      View in: PubMed   Mentions:    Fields:    
    104. Multiplicity: When many analytic plans are applied or many redundant studies are run, false-positive results are ensured. Eur J Clin Invest. 2022 08; 52(8):e13802. Powell K, Prasad V. PMID: 35488444.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    105. FDA precedents in drug approvals: Contradiction in promoting more treatment options. Eur J Cancer. 2022 07; 169:123-125. Olivier T, Prasad V. PMID: 35550951.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    106. Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials. JAMA Netw Open. 2022 05 02; 5(5):e2212327. Ahmed N, Vengalasetti Y, Haslam A, Prasad V. PMID: 35576006; PMCID: PMC9112068.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    107. FDA decisions on new oncological drugs. Lancet Oncol. 2022 05; 23(5):585-586. Benjamin DJ, Prasad V, Lythgoe MP. PMID: 35489341.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    108. Accelerated approval requirements for lurbinectedin. Lancet Oncol. 2022 05; 23(5):e206. Benjamin DJ, Prasad V. PMID: 35489350.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    109. The Effect of Hospital Visitor Policies on Patients, Their Visitors, and Health Care Providers During the COVID-19 Pandemic: A Systematic Review. Am J Med. 2022 10; 135(10):1158-1167.e3. Iness AN, Abaricia JO, Sawadogo W, Iness CM, Duesberg M, Cyrus J, Prasad V. PMID: 35472383; PMCID: PMC9035621.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsPHPublic Health
    110. Chaotic advection in a recirculating flow: Effect of a fluid-flexible-solid interaction. Chaos. 2022 Apr; 32(4):043122. Prasad V, Kulkarni SS, Sharma A. PMID: 35489862.
      View in: PubMed   Mentions:    Fields:    
    111. Frequency of survival to hospital discharge after cardiopulmonary resuscitation on FOX TV's The Resident. Eur J Emerg Med. 2022 04 01; 29(2):142-143. Herrera-Perez D, Gill J, Haslam A, Crain T, Klossner Q, Prasad V. PMID: 35210379.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    112. Tebentafusp in first-line melanoma trials: An outperforming outlier. Transl Oncol. 2022 Jun; 20:101408. Olivier T, Prasad V. PMID: 35364557; PMCID: PMC8968051.
      View in: PubMed   Mentions: 4  
    113. Targeted therapy in lung cancer: Are we closing the gap in years of life lost? Cancer Med. 2022 09; 11(18):3417-3424. Benjamin DJ, Haslam A, Gill J, Prasad V. PMID: 35315222; PMCID: PMC9487872.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    114. High US drug prices have global implications. BMJ. 2022 03 22; 376:o693. Jenei K, Prasad V, Lythgoe MP. PMID: 35318198.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    115. Characteristics of oncology podcasts: Attitudes, speakers, conflicts. J Cancer Policy. 2022 06; 32:100329. Akman EG, Powell K, Haslam A, Prasad V. PMID: 35560266.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    116. Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial. J Clin Oncol. 2022 05 10; 40(14):1596-1597. Olivier T, Prasad V. PMID: 35258990.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    117. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021. JAMA Netw Open. 2022 03 01; 5(3):e222265. Benjamin DJ, Xu A, Lythgoe MP, Prasad V. PMID: 35289858; PMCID: PMC8924721.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    118. Post-protocol therapy and informative censoring in the CANDOR study. Lancet Oncol. 2022 03; 23(3):e97. Meirson T, Markel G, Prasad V, Goodman AM, Mohyuddin GR. PMID: 35240098.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    119. Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials-Reply. JAMA Oncol. 2022 03 01; 8(3):480. Jenei K, Meyers DE, Prasad V. PMID: 34989805.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    120. Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. Eur J Cancer. 2022 05; 167:152-160. Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR. PMID: 35236569.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    121. Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020. Int J Cancer. 2022 06 01; 150(11):1905-1910. Kim MS, Xu A, Haslam A, Prasad V. PMID: 35182072.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    122. The use and meaning of the parachute metaphor in biomedicine: a citation analysis of a systematic review and a randomized trial of the parachute for freefall. J Comp Eff Res. 2022 04; 11(6):383-390. Xu A, Prasad V. PMID: 35189694.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    123. The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA. Transl Oncol. 2022 Apr; 18:101374. Olivier T, Prasad V. PMID: 35196605; PMCID: PMC8866737.
      View in: PubMed   Mentions: 10  
    124. Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. Eur J Cancer. 2022 03; 164:95-104. Maniar A, Haslam A, Prasad V. PMID: 35182927.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    125. Retrospective comparative effectiveness research: Will changing the analytical methods change the results? Int J Cancer. 2022 06 15; 150(12):1933-1940. Zaorsky NG, Wang X, Lehrer EJ, Tchelebi LT, Yeich A, Prasad VK, Chinchilli VM, Wang M. PMID: 35099077.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    126. The accelerated approval pathway in oncology: Balancing the benefits and potential harms. J Cancer Policy. 2022 06; 32:100323. Wayant C, Mohyuddin GR, Prasad V. PMID: 35560261.
      View in: PubMed   Mentions: 1     Fields:    
    127. Regulatory decisions diverge over aducanumab for Alzheimer's disease. BMJ. 2022 01 28; 376:e069780. Lythgoe MP, Jenei K, Prasad V. PMID: 35091420.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    128. The last word to new FDA draft guidance for cancer clinical trial eligibility criteria for patients with incurable cancer. J Cancer Policy. 2022 03; 31:100322. Lythgoe MP, Prasad V. PMID: 35559869.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    129. An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC). BMC Cancer. 2022 Jan 16; 22(1):70. Sharp J, Prasad V. PMID: 35034621; PMCID: PMC8761278.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    130. Reporting of Physicians' or Investigators' Choice of Treatment in Oncology Randomized Clinical Trials. JAMA Netw Open. 2022 01 04; 5(1):e2144770. Olivier T, Haslam A, Prasad V. PMID: 35061042; PMCID: PMC8783268.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    131. How Often do Medical Specialties Question the Practices that They Perform? An Empirical, Cross-Sectional Analysis of the Published Literature. Inquiry. 2022 Jan-Dec; 59:469580211061034. Haslam A, Powell K, Prasad V. PMID: 35322719; PMCID: PMC8961376.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    132. Comparison of Classification of Indications for Allogeneic and Autologous Transplant for Adults in ASTCT Guidelines and Evidence Available in Published Literature. JAMA Intern Med. 2022 01 01; 182(1):76-78. Kim MS, Cai J, Maniar A, Kartika T, Haslam A, Prasad V. PMID: 34491275; PMCID: PMC8424524.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    133. A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers. J Cancer Policy. 2022 03; 31:100319. Prasad V, Haslam A, Tuia J. PMID: 35559871.
      View in: PubMed   Mentions:    Fields:    
    134. Where are randomized trials necessary: Are smoking and parachutes good counterexamples? Eur J Clin Invest. 2022 05; 52(5):e13730. Powell K, Prasad V. PMID: 34913477.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    135. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action. JAMA Netw Open. 2021 12 01; 4(12):e2138793. Olivier T, Haslam A, Prasad V. PMID: 34905002; PMCID: PMC8672232.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    136. Has the Current Oncology Value Paradigm Forgotten Patients' Time?: Too Little of a Good Thing. JAMA Oncol. 2021 12 01; 7(12):1757-1758. Fundytus A, Prasad V, Booth CM. PMID: 34436535.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    137. The FDA's latest move to expand eligibility for oncology trials - a double-edged sword? Nat Rev Clin Oncol. 2021 12; 18(12):745-746. Lythgoe MP, Prasad V. PMID: 34535789.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    138. Artificial intelligence and magnetic resonance imaging may not make cancer screening better. J Cancer Policy. 2022 03; 31:100314. Powell K, Kim MS, Haslam A, Prasad V. PMID: 35559866.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    139. The frequency of assessment of progression in randomized oncology clinical trials. Cancer Rep (Hoboken). 2022 07; 5(7):e1527. Haslam A, Gill J, Prasad V. PMID: 34821077; PMCID: PMC9327664.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    140. Overall survival for oncology drugs approved for genomic indications. Eur J Cancer. 2022 01; 160:175-179. Haslam A, Kim MS, Prasad V. PMID: 34819251.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    141. Elacestrant in metastatic breast cancer: Is the "standard of care" meeting standard requirements? Transl Oncol. 2022 Jan; 15(1):101273. Olivier T, Prasad V. PMID: 34798371; PMCID: PMC8605291.
      View in: PubMed   Mentions:
    142. Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. Br J Haematol. 2022 03; 196(5):1274-1277. Banerjee R, Midha S, Kelkar AH, Goodman A, Prasad V, Mohyuddin GR. PMID: 34750805.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    143. The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy. Eur J Cancer. 2021 12; 159:56-59. Lythgoe MP, Olivier T, Prasad V. PMID: 34736043.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    144. Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020. JAMA Netw Open. 2021 11 01; 4(11):e2135123. Haslam A, Lythgoe MP, Greenstreet Akman E, Prasad V. PMID: 34792592; PMCID: PMC8603079.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    145. Implementation of MPOWER Package in the South-East Asia Region: Evidence from the WHO Report on the Global Tobacco Epidemic (2009-2021). Asian Pac J Cancer Prev. 2021 Nov 01; 22(S2):71-80. Kaur J, Rinkoo AV, Gouda HN, Prasad V, Pendse RN. PMID: 34780141.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    146. Tobacco Control in the South-East Asia Region: Accelerating Impact by Building on the Achievements and Navigating the Challenges. Asian Pac J Cancer Prev. 2021 11 01; 22(S2):3-5. Prasad V, Kaur J. PMID: 34780132.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    147. Cost-Effectiveness of Population Level and Individual Level Interventions to Combat Non-communicable Disease in Eastern Sub-Saharan Africa and South East Asia: A WHO-CHOICE Analysis. Int J Health Policy Manag. 2021 Nov 01; 10(11):724-733. Bertram MY, Chisholm D, Watts R, Waqanivalu T, Prasad V, Varghese C. PMID: 34273918; PMCID: PMC9278376.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    148. Tobacco Advertising, Promotion and Sponsorship in India and Indonesia: Present Regime and the Way Forward. Asian Pac J Cancer Prev. 2021 Nov 01; 22(S2):89-96. Chandra S, Rinkoo AV, Kaur J, Prasad V. PMID: 34780143.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    149. The Oncologic Drugs Advisory Committee Votes of April 2021-Implications for the Fate of Accelerated Approval. JAMA Oncol. 2021 11 01; 7(11):1607-1609. Powell K, Lythgoe MP, Prasad V. PMID: 34236432.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    150. Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020. J Cancer Policy. 2021 12; 30:100311. Jenei K, Raymakers A, Meyers DE, Prasad V. PMID: 35559802.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    151. Recommendation Reversals in Gastroenterology Clinical Practice Guidelines. J Can Assoc Gastroenterol. 2022 Apr; 5(2):98-99. Gholami R, Khan R, Ramkissoon A, Alabdulqader A, Gimpaya N, Bansal R, Scaffidi MA, Prasad V, Detsky AS, Baker JP, Grover SC. PMID: 35368318; PMCID: PMC8972276.
      View in: PubMed   Mentions:
    152. Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm. Transl Oncol. 2022 Jan; 15(1):101248. Olivier T, Prasad V. PMID: 34688044; PMCID: PMC8531666.
      View in: PubMed   Mentions: 6  
    153. An Empirical Analysis of Precision Previvorship: Are Familial and High-Risk Cancer Preventive Programs Evidence Based? Am J Med. 2022 02; 135(2):179-183. Powell K, Haslam A, Prasad V. PMID: 34678212.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    154. Multi-Cancer Screening Tests: Communicating About Risks Should be Prioritized. Am J Med. 2022 04; 135(4):413-415. Olivier T, Gill J, Prasad V. PMID: 34655543.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    155. Colorectal cancer screening at a younger age: pitfalls in the model-based recommendation of the USPSTF. BMJ Evid Based Med. 2022 08; 27(4):206-208. Powell K, Prasad V. PMID: 34635479.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    156. Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study. Cancer. 2022 01 15; 128(2):311-316. Meyers DE, Meyers BS, Chisamore TM, Wright K, Gyawali B, Prasad V, Sullivan R, Booth CM. PMID: 34614198.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    157. The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years. JAMA Oncol. 2021 10 01; 7(10):1569-1570. Jenei K, Meyers DE, Prasad V. PMID: 34436541; PMCID: PMC8391769.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    158. Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination. Front Med. 2021 12; 15(6):938-941. Kulkarni PA, Prasad V. PMID: 34595694; PMCID: PMC8482953.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    159. How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond. Eur J Cancer. 2021 11; 157:68-70. Lythgoe MP, Prasad V. PMID: 34487987.
      View in: PubMed   Mentions: 2     Fields:    
    160. The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting. Mayo Clin Proc. 2021 09; 96(9):2305-2308. Gill J, Sarpatwari A, Prasad V. PMID: 34481596.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    161. Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review. JAMA Netw Open. 2021 09 01; 4(9):e2124728. Sharp J, Khaki AR, Prasad V. PMID: 34570209; PMCID: PMC8477261.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    162. An Analysis of 5 Years of Randomized Trials in Gastroenterology and Hepatology Reveals 52 Medical Reversals. Dig Dis Sci. 2022 06; 67(6):2011-2018. Yopes MC, Mozeika AM, Liebling S, Haslam A, Prasad V, Lebwohl B. PMID: 34463882.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    163. Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. Eur J Cancer. 2021 10; 156:164-174. Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V. PMID: 34454318.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    164. Idecabtagene vicleucel: questions regarding the appropriate role and cost. Br J Haematol. 2022 01; 196(2):e15-e16. Powell K, Russler-Germain D, Prasad V. PMID: 34402527.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    165. Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients diverge. Eur J Cancer. 2021 09; 155:163-167. Kim MS, Prasad V. PMID: 34388514.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    166. The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009-2018. BMC Cancer. 2021 Aug 03; 21(1):889. Haslam A, Gill J, Crain T, Herrera-Perez D, Chen EY, Hilal T, Kim MS, Prasad V. PMID: 34344325; PMCID: PMC8336285.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    167. After COVID-19, telemedicine may be used in addition to usual care and not in lieu of: Implications for health systems. Int J Cancer. 2021 11 01; 149(9):1723-1724. Gill J, Prasad V. PMID: 34313349; PMCID: PMC8426807.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    168. Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials. J Clin Epidemiol. 2021 11; 139:80-86. Olivier T, Haslam A, Prasad V. PMID: 34311054.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    169. Characteristics of Registered Studies of Chimeric Antigen Receptor Therapies: A Systematic Review. JAMA Netw Open. 2021 07 01; 4(7):e2115668. Banerjee R, Prasad V. PMID: 34236412; PMCID: PMC8267610.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    170. New drugs and options can enhance patient outcomes: But can they also erode them? Eur J Cancer. 2021 09; 154:1-3. Kim MS, Prasad V. PMID: 34217009.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    171. Reliable, cheap, fast and few: What is the best study for assessing medical practices? Randomized controlled trials or synthetic control arms? Eur J Clin Invest. 2021 Aug; 51(8):e13580. Prasad V. PMID: 33909291.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    172. The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt. Leuk Lymphoma. 2021 11; 62(11):2793-2795. Mohyuddin GR, Ouchveridze E, Goodman A, Prasad V. PMID: 34114943.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    173. When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100. BMJ Evid Based Med. 2022 06; 27(3):151-152. Kim MS, Prasad V. PMID: 34083211.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    174. The regulatory saga of fedratinib. J Oncol Pharm Pract. 2021 Jul; 27(5):1248-1250. Khal S, Prasad V, Palumbo A. PMID: 34013823.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    175. Assessment of New Molecular Entities Approved for Cancer Treatment in 2020. JAMA Netw Open. 2021 05 03; 4(5):e2112558. Smith CEP, Prasad V. PMID: 34047795; PMCID: PMC8164099.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    176. Multiple myeloma triplet therapies: baseline characteristics and control groups. Lancet. 2021 05 01; 397(10285):1620-1621. Mohyuddin GR, Abdallah AO, McClune B, Goodman A, Prasad V. PMID: 33933200.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    177. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. JAMA Oncol. 2021 May 01; 7(5):728-734. Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B, Booth CM. PMID: 33764385; PMCID: PMC7995135.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    178. Accurate accounting of caplacizumab cost effectiveness. Lancet Haematol. 2021 05; 8(5):e315. Goshua G, Prasad V, Lee AI, Bendapudi PK. PMID: 33894166.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    179. Low-Dose Computed Tomographic Screening for Lung Cancer: Time to Implement or Unresolved Questions? J Gen Intern Med. 2021 10; 36(10):3202-3204. Desai A, Prasad V. PMID: 33904047; PMCID: PMC8481428.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    180. Industry payments to US physicians for cancer therapeutics: An analysis of the 2016-2018 open payments datasets. J Cancer Policy. 2021 06; 28:100283. Meyers DE, Chisamore TM, McInnes MDF, Gyawali B, Prasad V, Booth CM. PMID: 35559912.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    181. Old-fashioned Intelligence Will Always Be Needed in Medicine. Eur Urol Focus. 2021 07; 7(4):685-686. Powell K, Prasad V. PMID: 33824086.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    182. Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review. JAMA Netw Open. 2021 04 01; 4(4):e218084. Mohyuddin GR, Koehn K, Abdallah AO, Goodman AM, Prasad V. PMID: 33909053; PMCID: PMC8082314.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    183. Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematol. 2021 Apr; 8(4):e299-e304. Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, Prasad V. PMID: 33770485.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    184. Approval and Coverage of Cancer Drugs in England, Canada, and the US. JAMA Intern Med. 2021 04 01; 181(4):509-510. Prasad V, Kim MS. PMID: 33616600.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    185. Pembrolizumab for Non-Muscle-Invasive Bladder Cancer-A Costly Therapy in Search of Evidence. JAMA Oncol. 2021 04 01; 7(4):501-502. Gill J, Prasad V. PMID: 33377964.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    186. Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib? Eur Urol. 2021 06; 79(6):710-712. Kwon DH, Booth CM, Prasad V. PMID: 33722420.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    187. Improvement of Pediatric Liver Core Biopsy Adequacy by Reducing Laboratory-Related Tissue Fragmentation and Increasing Portal Tract Yield. Am J Clin Pathol. 2021 02 11; 155(3):461-469. Liang J, Abbuhl MF, Wang H, Prasad V, Coogan A. PMID: 32915192.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    188. Case report of a skip segment Hirschsprung's disease: A real phenomenon. Int J Surg Case Rep. 2021 Mar; 80:105630. El-Gohary Y, Skerritt C, Prasad V, Halaweish I, Wood RJ. PMID: 33592418; PMCID: PMC7893424.
      View in: PubMed   Mentions:
    189. Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018. JAMA Intern Med. 2021 02 01; 181(2):162-167. DeMartino PC, Miljkovic MD, Prasad V. PMID: 33165499; PMCID: PMC7653539.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    190. Drug Approvals in Hepatocellular Carcinoma-Filling the Nonexistent Gap? JAMA Oncol. 2021 02 01; 7(2):173-174. Desai A, Prasad V. PMID: 33151259.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    191. Targeted Cancer Therapies. Am Fam Physician. 2021 02 01; 103(3):155-163. Smith CEP, Prasad V. PMID: 33507053.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    192. Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors. JTO Clin Res Rep. 2021 Apr; 2(4):100149. Kareff SA, Samtani S, Burotto M, Prasad V, Kim C. PMID: 34590006; PMCID: PMC8474294.
      View in: PubMed   Mentions: 1  
    193. Persistent challenges with treating multiple myeloma early. Blood. 2021 01 28; 137(4):456-458. Goodman AM, Kim MS, Prasad V. PMID: 33236046.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    194. N of 1 Data Sharing: The Impact of Data Sharing within the Hematology-Oncology Drug Products Division of the US FDA. Trends Cancer. 2021 05; 7(5):395-399. Gill J, Prasad V. PMID: 33431338.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    195. Application of ASCO Value Framework to Treatment Advances in Hepatocellular Carcinoma. JCO Oncol Pract. 2021 04; 17(4):e461-e468. Chen EY, Cook M, Deig C, Arastu A, Prasad V, Nabavizadeh N, Lopez CD, Kardosh A. PMID: 33411593.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    196. Considering benefit and risk before routinely recommending SpaceOAR. Lancet Oncol. 2021 01; 22(1):11-13. Hall WA, Tree AC, Dearnaley D, Parker CC, Prasad V, Roach M, Lawton CAF. PMID: 33387489; PMCID: PMC8882263.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    197. Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19. Nat Rev Clin Oncol. 2021 01; 18(1):7-8. Banerjee R, Prasad V. PMID: 33139895; PMCID: PMC7604917.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    198. Drug repurposing in oncology - Authors' reply. Lancet Oncol. 2020 12; 21(12):e544. Tran AA, Prasad V. PMID: 33271101.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    199. Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. BMJ Evid Based Med. 2022 02; 27(1):46-54. Torgerson T, Wayant C, Cosgrove L, Akl EA, Checketts J, Dal Re R, Gill J, Grover SC, Khan N, Khan R, Marušic A, McCoy MS, Mitchell A, Prasad V, Vassar M. PMID: 33177167.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    200. Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing. Eur J Cancer. 2020 12; 141:152-161. Rosen K, Prasad V, Chen EY. PMID: 33160265.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    201. Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response? Eur J Cancer. 2020 11; 139:20-26. Tao DL, Kartika T, Tran A, Prasad V. PMID: 32957010.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    202. Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy. Lancet Oncol. 2020 09; 21(9):1134-1136. Tran AA, Prasad V. PMID: 32888447.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    203. The response rate of alternative treatments for drugs approved on the basis of response rate. Int J Cancer. 2021 02 01; 148(3):713-722. Haslam A, Gill J, Prasad V. PMID: 32700797.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    204. The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No. Ann Oncol. 2020 09; 31(9):1112-1114. Prasad V, Addeo A. PMID: 32771305.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    205. Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration. JAMA Intern Med. 2020 08 01; 180(8):1108-1115. Hilal T, Gonzalez-Velez M, Prasad V. PMID: 32539071; PMCID: PMC7296449.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    206. Response to Comment on "Replacing the NCCN's Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?" Pharmacoeconomics. 2020 08; 38(8):895-896. Tran A, Prasad V. PMID: 32588391.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    207. Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia. Leuk Res. 2020 09; 96:106420. Tran AA, Miljkovic M, Prasad V. PMID: 32712431.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    208. US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation. Cancer. 2020 10 01; 126(19):4270-4272. Kim MS, Prasad V. PMID: 32644193.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    209. Replacing the NCCN's Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice? Pharmacoeconomics. 2020 07; 38(7):729-731. Tran AA, Prasad V. PMID: 32328981.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    210. Are Observational, Real-World Studies Suitable to Make Cancer Treatment Recommendations? JAMA Netw Open. 2020 07 01; 3(7):e2012119. Banerjee R, Prasad V. PMID: 32729916.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    211. A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer. Trends Cancer. 2020 09; 6(9):736-738. Gill J, Cetnar JP, Prasad V. PMID: 32616400.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    212. The necessity of continuing to ban tobacco use in public places post-COVID-19. East Mediterr Health J. 2020 Jun 24; 26(6):630-632. El-Awa F, Fraser CP, Adib K, Hammerich A, Abdel Latif N, Fayokun R, Prasad V, Fu D, Vestal G, Schotte K, Gouda H, St Claire S. PMID: 32621493.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    213. Shifting, overlapping and expanding use of "precision oncology" terminology: a retrospective literature analysis. BMJ Open. 2020 06 07; 10(6):e036357. Tran A, Klossner Q, Crain T, Prasad V. PMID: 32513891; PMCID: PMC7282391.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    214. FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019. JAMA Intern Med. 2020 06 01; 180(6):912-914. Chen EY, Haslam A, Prasad V. PMID: 32338703; PMCID: PMC7186918.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    215. Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice? Cancer. 2020 09 15; 126(18):4087-4088. Nishikawa G, Booth C, Prasad V. PMID: 32459369.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    216. Estimation of US patients with cancer who may respond to cytotoxic chemotherapy. Future Sci OA. 2020 May 25; 6(8):FSO600. Maldonado EB, Parsons S, Chen EY, Haslam A, Prasad V. PMID: 32983564; PMCID: PMC7491026.
      View in: PubMed   Mentions: 7  
    217. Frequency of Medical Reversal Among Published Randomized Controlled Trials Assessing Cardiopulmonary Resuscitation (CPR). Mayo Clin Proc. 2020 05; 95(5):889-910. Herrera-Perez D, Fox-Lee R, Bien J, Prasad V. PMID: 32370852.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    218. The Reply. Am J Med. 2020 05; 133(5):e202. Mandrola J, Cifu A, Prasad V, Foy A. PMID: 32450948.
      View in: PubMed   Mentions:    Fields:    
    219. Comparison of Industry Payments in 2017 With Annual Salary in a Cohort of Academic Oncologists. JAMA Intern Med. 2020 05 01; 180(5):797-799. Gill J, Haslam A, Crain T, Herrera-Perez D, Prasad V. PMID: 32202604; PMCID: PMC7091392.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    220. The evidence landscape in precision medicine. Sci Transl Med. 2020 04 22; 12(540). Hey SP, Gerlach CV, Dunlap G, Prasad V, Kesselheim AS. PMID: 32321867.
      View in: PubMed   Mentions: 4     Fields:    
    221. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials. J Natl Compr Canc Netw. 2020 04; 18(4):428-433. Hazim A, Mills G, Prasad V, Haslam A, Chen EY. PMID: 32259790.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    222. Comparison of Drugs Used for Adjuvant and Metastatic Therapy of Colon, Breast, and Non-Small Cell Lung Cancers. JAMA Netw Open. 2020 04 01; 3(4):e202488. Parsons S, Maldonado EB, Prasad V. PMID: 32275321; PMCID: PMC7148439.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    223. Acute histologic inflammatory activity and postoperative outcomes in pediatric patients with ulcerative colitis. Am J Surg. 2020 04; 219(4):592-597. Onwuka E, Huntington J, Onwuka A, Prasad V, Nwomeh B. PMID: 32209240.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    224. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs. JAMA Netw Open. 2020 03 02; 3(3):e200423. Haslam A, Gill J, Prasad V. PMID: 32150268; PMCID: PMC7063495.
      View in: PubMed   Mentions: 80     Fields:    Translation:Humans
    225. Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials. JAMA Netw Open. 2020 03 02; 3(3):e200363. Haslam A, Herrera-Perez D, Gill J, Prasad V. PMID: 32129865; PMCID: PMC7057133.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    226. Statistical significance and clinical evidence - Authors' reply. Lancet Oncol. 2020 03; 21(3):e119. Prasad V, Booth CM. PMID: 32135103.
      View in: PubMed   Mentions:    Fields:    
    227. News Coverage of the American Cancer Society's Update to Colorectal Cancer Screening Guidelines. Mayo Clin Proc. 2020 03; 95(3):617-618. Krigel A, Prasad VK, Lebwohl B. PMID: 32138893.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    228. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2020 02 27; 382(9):876. Prasad V. PMID: 32101676.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    229. Medical Reversals in Family Practice: A Review. Curr Ther Res Clin Exp. 2020; 92:100579. Haslam A, Livingston C, Prasad V. PMID: 32180846; PMCID: PMC7063107.
      View in: PubMed   Mentions: 1     Fields:    
    230. An Empirical Analysis of Noninferiority Studies in Oncology: Are They Good Enough? J Natl Compr Canc Netw. 2020 02; 18(2):161-167. Haslam A, Gill J, Prasad V. PMID: 32023529.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    231. Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration's Actions. Mayo Clin Proc. 2020 02; 95(2):424-426. Haslam A, Gill J, Prasad V. PMID: 32029095.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    232. The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab. JAMA Intern Med. 2020 02 01; 180(2):315-317. Kim MS, Prasad V. PMID: 31657842; PMCID: PMC6820044.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    233. Characteristics of Public Comments Submitted to State Health Technology Assessment Programs in Oregon and Washington. JAMA Intern Med. 2020 02 01; 180(2):329-331. Ahn R, Herrera-Perez D, Prasad V. PMID: 31710334; PMCID: PMC6865292.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    234. Comparison of three multi-cryoprotectant loading protocols for vitrification of porcine articular cartilage. Cryobiology. 2020 02 01; 92:151-160. Wu K, Shardt N, Laouar L, Chen Z, Prasad V, Elliott JAW, Jomha NM. PMID: 31917159.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    235. Our best weapons against cancer are not magic bullets. Nature. 2020 01; 577(7791):451. Prasad V. PMID: 31965108.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    236. Concerning survival signal for eltrombopag in MDS/AML. Leuk Lymphoma. 2020 04; 61(4):1002-1003. Tao D, Prasad V. PMID: 31786967.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    237. Multiplicity in oncology randomised controlled trials: a threat to medical evidence? Lancet Oncol. 2019 12; 20(12):1638-1640. Prasad V, Booth CM. PMID: 31797779.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    238. Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data. J Natl Compr Canc Netw. 2019 12; 17(12):1456-1458. Khaki AR, Gadi VK, Prasad V. PMID: 31805524.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    239. Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours. Curr Oncol. 2019 12; 26(6):e791-e792. Gay ND, Tao D, Prasad V. PMID: 31896950; PMCID: PMC6927779.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    240. Examining the Use of Real-World Evidence in the Regulatory Process. Clin Pharmacol Ther. 2020 04; 107(4):843-852. Beaulieu-Jones BK, Finlayson SG, Yuan W, Altman RB, Kohane IS, Prasad V, Yu KH. PMID: 31562770; PMCID: PMC7093234.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    241. Medical reversals in low- and middle-income countries. Int J Health Plann Manage. 2020 Mar; 35(2):631-638. Haslam A, Prasad V, Livingston C. PMID: 31710144.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    242. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib. JAMA Netw Open. 2019 11 01; 2(11):e1916091. de Almeida Carvalho LM, de Oliveira Sapori Avelar S, Haslam A, Gill J, Prasad V. PMID: 31755953; PMCID: PMC6902826.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    243. A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment. Res Pract Thromb Haemost. 2020 Jan; 4(1):19-22. Gill J, Prasad V. PMID: 31989081; PMCID: PMC6971317.
      View in: PubMed   Mentions: 1  
    244. Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration. Cancer Med. 2019 11; 8(15):6651-6661. Aspinall SL, Zhao X, Geraci MC, Good CB, Cunningham FE, Heron BB, Becker D, Lee S, Prasad V, Targeted Therapies in Veterans with RCC Study Group. PMID: 31536684; PMCID: PMC6825975.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    245. The Reply. Am J Med. 2019 09; 132(9):e719. Mandrola J, Cifu A, Prasad V, Foy A. PMID: 31606062.
      View in: PubMed   Mentions:    Fields:    
    246. A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda. J Cancer Res Clin Oncol. 2019 Sep; 145(9):2303-2311. Luo J, Nishikawa G, Prasad V. PMID: 31396700.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    247. A reality check of the accelerated approval of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2019 11; 16(11):656-658. Gill J, Prasad V. PMID: 31383994.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    248. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. JAMA Intern Med. 2019 07 01; 179(7):915-921. Chen EY, Raghunathan V, Prasad V. PMID: 31135822; PMCID: PMC6547222.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    249. A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. Elife. 2019 06 11; 8. Herrera-Perez D, Haslam A, Crain T, Gill J, Livingston C, Kaestner V, Hayes M, Morgan D, Cifu AS, Prasad V. PMID: 31182188; PMCID: PMC6559784.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    250. Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice? Mayo Clin Proc. 2019 06; 94(6):951-956. Chapa J, Haslam A, Prasad V. PMID: 31171133.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    251. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration. JAMA Oncol. 2019 Jun 01; 5(6):887-892. Hilal T, Sonbol MB, Prasad V. PMID: 31046071; PMCID: PMC6499129.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    252. Real-world Evidence-What Does It Really Mean? JAMA Oncol. 2019 Jun 01; 5(6):781-783. Nabhan C, Klink A, Prasad V. PMID: 31095259.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    253. Registration studies - when should patients be deemed ineligible for aggressive therapy? Nat Rev Clin Oncol. 2019 06; 16(6):333-334. Cook RJ, Gill J, Prasad V. PMID: 30778146.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    254. Confirmatory Trials for Drugs Approved on a Single Trial. Circ Cardiovasc Qual Outcomes. 2019 06; 12(6):e005494. Haslam A, Prasad V. PMID: 31137954.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    255. Should Evidence Come with an Expiration Date? J Gen Intern Med. 2019 07; 34(7):1356-1357. Greene P, Prasad V, Cifu A. PMID: 31062228; PMCID: PMC6614217.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    256. Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals. JAMA Netw Open. 2019 05 03; 2(5):e193981. Kim MS, Prasad V. PMID: 31099871; PMCID: PMC6537809.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    257. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019 05 03; 2(5):e192535. Haslam A, Prasad V. PMID: 31050774; PMCID: PMC6503493.
      View in: PubMed   Mentions: 487     Fields:    Translation:Humans
    258. Reply to C.J. Sweeney et al. J Clin Oncol. 2019 07 01; 37(19):1680-1681. Parikh RB, Prasad V. PMID: 31050910; PMCID: PMC6879314.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    259. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials. JAMA Intern Med. 2019 05 01; 179(5):642-647. Chen EY, Joshi SK, Tran A, Prasad V. PMID: 30933235; PMCID: PMC6503556.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    260. Case Reports in the Age of Twitter. Am J Med. 2019 10; 132(10):e725-e726. Cifu AS, Vandross AL, Prasad V. PMID: 30998916.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    261. Testing Healthcare Workers for Latent Tuberculosis: Is It Evidence Based, Bio-Plausible, Both, Or Neither? Am J Med. 2019 11; 132(11):1260-1261. Gill J, Prasad V. PMID: 30946831.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    262. Recenti Prog Med. 2019 04; 110(4):156-158. Mandrola J, Cifu A, Prasad V, Foy A. PMID: 31066360.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    263. Testing for blinding in sham-controlled studies for procedural interventions: the third-party video method. CMAJ. 2019 03 11; 191(10):E272-E273. Gill J, Prasad V. PMID: 30858182; PMCID: PMC6411475.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    264. The Case for Being a Medical Conservative. Am J Med. 2019 08; 132(8):900-901. Mandrola J, Cifu A, Prasad V, Foy A. PMID: 30851263.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    265. Improving the design of pivotal clinical trials. Clin Adv Hematol Oncol. 2019 Mar; 17(3):150-152. Prasad VK. PMID: 30969951.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    266. Cancer screening: A modest proposal for prevention. Cleve Clin J Med. 2019 03; 86(3):157-160. Kim MS, Nishikawa G, Prasad V. PMID: 30849032.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    267. Where Does the Blame for High Health Care Costs Go? An Empirical Analysis of Newspaper and Journal Articles Criticizing Health Care Costs. Am J Med. 2019 06; 132(6):718-721. Haslam A, Crain T, Gill J, Herrera-Perez D, Prasad V. PMID: 30639552.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    268. Metastasis-Free Survival in Prostate Cancer: Faster Drug Approvals, Better Drugs? J Clin Oncol. 2019 02 01; 37(4):266-268. Parikh RB, Prasad V. PMID: 30532985.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    269. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. Eur J Cancer. 2019 01; 106:196-211. Haslam A, Hey SP, Gill J, Prasad V. PMID: 30528804.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    270. Addendum: Low-value approvals and high prices might incentivize ineffective drug development. Nat Rev Clin Oncol. 2018 12; 15(12):787. Prasad V, McCabe C, Mailankody S. PMID: 30420734.
      View in: PubMed   Mentions:    Fields:    
    271. Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission. Nat Rev Clin Oncol. 2018 12; 15(12):727-728. Hilal T, Prasad V. PMID: 30181661.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    272. Moving Precision Oncology Forward Amid Myths and Misconceptions-Reply. JAMA Oncol. 2018 12 01; 4(12):1790. Marquart J, Chen EY, Prasad V. PMID: 30419080.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    273. Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-Reply. JAMA Oncol. 2018 12 01; 4(12):1785-1786. Hernandez I, Prasad V, Gellad WF. PMID: 30325998.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    274. Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? Cardiovasc Drugs Ther. 2018 12; 32(6):637. Ahn R, Prasad V. PMID: 30276760.
      View in: PubMed   Mentions:    Fields:    
    275. Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? Cardiovasc Drugs Ther. 2018 12; 32(6):633-635. Ahn R, Prasad V. PMID: 30232657.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    276. Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers? Eur J Cancer. 2018 11; 104:252-253. Shanbhag S, Prasad V. PMID: 30342911.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    277. Inconsistent Reporting of Potential Conflicts of Interest. JAMA Intern Med. 2018 10 01; 178(10):1424-1425. Prasad V. PMID: 30105361.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    278. Inconsistent Reporting of Potential Conflicts of Interest. JAMA Oncol. 2018 10 01; 4(10):1439. Prasad V. PMID: 30128488.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    279. Meaningful and Accurate Disclosure of Conflict of Interest at the ASTRO National Meeting: A Need for Reassessment of Current Policies. J Oncol Pract. 2018 Sep 27; JOP1800121. Ahmed AA, Yoo SK, Mehta S, Holliday EB, Deville C, Vapiwala N, Wilson LD, Jagsi R, Prasad V, Thomas CR. PMID: 30260714.
      View in: PubMed   Mentions: 1     Fields:    
    280. Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were. BMJ. 2018 Sep 19; 362:k3783. Nishikawa G, Prasad V. PMID: 30232089.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    281. The Tradeoff of Cancer Drug Regulatory Policy: Faster Approvals for One Means Less Knowledge for Another. Am J Med. 2019 03; 132(3):e509-e511. Tao D, Schott S, Prasad V. PMID: 30201241.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    282. Choice of control group in randomised trials of cancer medicine: are we testing trivialities? Lancet Oncol. 2018 09; 19(9):1150-1152. Tao D, Prasad V. PMID: 30191836.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    283. Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies-Reply. JAMA Oncol. 2018 09 01; 4(9):1300-1301. Prasad V, Kaestner V, Mailankody S. PMID: 29978197.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    284. Inconsistent Reporting of Potential Conflicts of Interest. JAMA Pediatr. 2018 09 01; 172(9):886. Prasad V. PMID: 30073291.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    285. Improving observational studies in the era of big data. Lancet. 2018 09 01; 392(10149):716-717. Gill J, Prasad V. PMID: 30191816.
      View in: PubMed   Mentions: 11     Fields:    
    286. A pooled analysis of published, basket trials in cancer medicine. Eur J Cancer. 2018 09; 101:244-250. Hazim A, Prasad V. PMID: 30096705.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    287. The Necessity of Sham Controls. Am J Med. 2019 02; 132(2):e29-e30. Prasad V, Cifu AS. PMID: 30076810.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    288. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology. JAMA Oncol. 2018 08 01; 4(8):1093-1098. Marquart J, Chen EY, Prasad V. PMID: 29710180; PMCID: PMC6143048.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    289. A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. Eur J Cancer. 2018 09; 101:143-151. Nishikawa G, Luo J, Prasad V. PMID: 30059818.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    290. Inconsistent Reporting of Potential Conflicts of Interest. JAMA. 2018 07 24; 320(4):408. Prasad V. PMID: 30043054.
      View in: PubMed   Mentions:    Fields:    
    291. Multivitamins Do Not Reduce Cardiovascular Disease and Mortality and Should Not Be Taken for This Purpose: How Do We Know That? Circ Cardiovasc Qual Outcomes. 2018 07; 11(7):e004886. Haslam A, Prasad V. PMID: 29991647.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    292. Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy-Reply. JAMA Pediatr. 2018 07 01; 172(7):701-702. Prasad V. PMID: 29800980.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    293. Low-value approvals and high prices might incentivize ineffective drug development. Nat Rev Clin Oncol. 2018 07; 15(7):399-400. Prasad V, McCabe C, Mailankody S. PMID: 29760505.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    294. PFO closure for secondary stroke prevention: is the discussion closed? J Thromb Thrombolysis. 2018 Jul; 46(1):74-76. Shatzel JJ, Daughety MM, Prasad V, DeLoughery TG. PMID: 29464458.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    295. Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy. JAMA Oncol. 2018 07 01; 4(7):994-996. Hernandez I, Prasad V, Gellad WF. PMID: 29710129; PMCID: PMC6145722.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    296. Direct-to-Consumer Genetic Testing: The Implications of the US FDA's First Marketing Authorization for BRCA Mutation Testing. JAMA. 2018 Jun 19; 319(23):2377-2378. Gill J, Obley AJ, Prasad V. PMID: 29800087.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    297. The need to assess financial adverse events. Lancet Haematol. 2018 Nov; 5(11):e508-e509. Nastoupil LJ, Prasad V, Flowers CR. PMID: 29907551.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    298. If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis. J Gen Intern Med. 2018 08; 33(8):1213-1214. Deloughery EP, Prasad V. PMID: 29869138; PMCID: PMC6082210.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    299. Concerns About the Approval of Nusinersen Sodium by the US Food and Drug Administration. JAMA Intern Med. 2018 06 01; 178(6):743-744. Gerrity MS, Prasad V, Obley AJ. PMID: 29710299.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    300. Assessing Pharmaceutical Research and Development Costs-Reply. JAMA Intern Med. 2018 04 01; 178(4):588-589. Prasad V, Mailankody S. PMID: 29610885.
      View in: PubMed   Mentions: 2     Fields:    
    301. Overall Survival vs Disease-Specific Survival-Reply. JAMA Oncol. 2018 04 01; 4(4):586-587. Mailankody S, Prasad V. PMID: 29167883.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    302. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study. BMJ. 2018 03 07; 360:k668. Wagner J, Marquart J, Ruby J, Lammers A, Mailankody S, Kaestner V, Prasad V. PMID: 29514787; PMCID: PMC5838851.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    303. Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings. Hastings Cent Rep. 2018 Mar; 48(2):10-13. Hayes MJ, Prasad V. PMID: 29590518.
      View in: PubMed   Mentions: 11     Fields:    
    304. Nusinersen for Spinal Muscular Atrophy: Are We Paying Too Much for Too Little? JAMA Pediatr. 2018 02 01; 172(2):123-125. Prasad V. PMID: 29228077.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    305. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers. JAMA Oncol. 2018 Feb 01; 4(2):157-158. Prasad V, Kaestner V, Mailankody S. PMID: 29285544.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCells
    306. The relation between publication rate and financial conflict of interest among physician authors of high-impact oncology publications: an observational study. CMAJ Open. 2018 Jan 30; 6(1):E57-E62. Kaestner V, Edmiston JB, Prasad V. PMID: 29382668; PMCID: PMC5878961.
      View in: PubMed   Mentions: 2     Fields:    
    307. Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes. CMAJ Open. 2018 Jan 15; 6(1):E31-E38. Hayes MJ, Kaestner V, Mailankody S, Prasad V. PMID: 29343497; PMCID: PMC5878948.
      View in: PubMed   Mentions: 6     Fields:    
    308. Pemetrexed in Nonsquamous Non-Small-Cell Lung Cancer: The Billion Dollar Subgroup Analysis. JAMA Oncol. 2018 Jan 01; 4(1):17-18. Gyawali B, Prasad V. PMID: 28750129.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    309. Non-Inferiority Trials in Medicine: Practice Changing or a Self-Fulfilling Prophecy? J Gen Intern Med. 2018 01; 33(1):3-5. Prasad V. PMID: 28980180; PMCID: PMC5756169.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    310. Is "Precision Medicine" Ready to Use in Primary Care Practice? No: It Is Barely Ready for Testing. Am Fam Physician. 2017 Dec 15; 96(12):769-770. Prasad V, Obley A. PMID: 29431373.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    311. Clinically meaningful benefit: real world use compared against the American and European guidelines. Blood Cancer J. 2017 12 14; 7(12):645. Dreicer JJ, Mailankody S, Fakhrejahani F, Prasad V. PMID: 29238046; PMCID: PMC5802502.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    312. Overestimating the Benefit of Cancer Drugs. JAMA Oncol. 2017 12 01; 3(12):1737-1738. Prasad V. PMID: 28715568.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    313. Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals. Blood Cancer J. 2017 11 30; 7(12):637. Lammers A, Wang R, Cetnar J, Prasad V. PMID: 29187747; PMCID: PMC5802585.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    314. Me too-drugs with limited benefits - the tale of regorafenib for HCC. Nat Rev Clin Oncol. 2018 01; 15(1):62. Gyawali B, Prasad V. PMID: 29182165.
      View in: PubMed   Mentions: 4     Fields:    
    315. Is "Do Everything!" Always Appropriate?-Reply. JAMA Oncol. 2017 11 01; 3(11):1588. Beer TM, Prasad V. PMID: 28817761.
      View in: PubMed   Mentions: 1     Fields:    
    316. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. JAMA Intern Med. 2017 11 01; 177(11):1569-1575. Prasad V, Mailankody S. PMID: 28892524; PMCID: PMC5710275.
      View in: PubMed   Mentions: 120     Fields:    Translation:Humans
    317. Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat Rev Clin Oncol. 2018 01; 15(1):11-12. Prasad V. PMID: 28975930.
      View in: PubMed   Mentions: 87     Fields:    Translation:Humans
    318. Do cancer drugs improve survival or quality of life? BMJ. 2017 10 04; 359:j4528. Prasad V. PMID: 28978548; PMCID: PMC5695531.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    319. Conflicts of interest in Twitter. Lancet Haematol. 2017 09; 4(9):e408-e409. Kaestner V, Brown A, Tao D, Prasad V. PMID: 28863800.
      View in: PubMed   Mentions: 8     Fields:    
    320. Evolocumab in Patients with Cardiovascular Disease. N Engl J Med. 2017 08 24; 377(8):786-7. Redberg RF, Prasad V. PMID: 28836420.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    321. A further strategy to combat the high price of anticancer drugs. Nat Rev Clin Oncol. 2017 10; 14(10):629. Prasad V, De Jesús K, Mailankody S. PMID: 28829055.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    322. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med. 2017 07 21; 15(1):134. Kemp R, Prasad V. PMID: 28728605; PMCID: PMC5520356.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    323. Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC. Nat Rev Clin Oncol. 2017 11; 14(11):653-654. Gyawali B, Prasad V. PMID: 28719584.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    324. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Semin Oncol. 2017 04; 44(2):132-135. Prasad V, Kaestner V. PMID: 28923211.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    325. Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World. JAMA Oncol. 2017 07 01; 3(7):889-890. Mailankody S, Prasad V. PMID: 27892992.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    326. Limitations Concerning the Association of Physician Sex and Patient Outcomes. JAMA Intern Med. 2017 07 01; 177(7):1058. Friedberg MW, Gellad WF, Prasad V. PMID: 28672361.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    327. Financial Conflict of Interest and Academic Influence Among Experts Speaking on Behalf of the Pharmaceutical Industry at the US Food and Drug Administration's Oncologic Drugs Advisory Committee Meetings. Mayo Clin Proc. 2017 07; 92(7):1164-1166. Lammers A, Edmiston J, Kaestner V, Prasad V. PMID: 28688469.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    328. Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is? Cancer. 2017 10 15; 123(20):3872-3874. Goldstein DA, Bilal U, Prasad V. PMID: 28662268.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    329. Pharmaceutical Marketing for Rare Diseases: Regulating Drug Company Promotion in an Era of Unprecedented Advertisement. JAMA. 2017 06 27; 317(24):2479-2480. Mailankody S, Prasad V. PMID: 28520871.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    330. Combining drugs and extending treatment - a PFS end point is not sufficient. Nat Rev Clin Oncol. 2017 09; 14(9):521-522. Gyawali B, Prasad V. PMID: 28534528.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    331. Extrarenal Wilms Tumor With Skeletal and Glial Differentiation. Int J Surg Pathol. 2018 Feb; 26(1):34. Tan GC, Prasad V. PMID: 28508688.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    332. Closed Financial Loops: When They Happen in Government, They're Called Corruption; in Medicine, They're Just a Footnote. Hastings Cent Rep. 2017 May; 47(3):9-14. De Jesus-Morales K, Prasad V. PMID: 28543414.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    333. Curbing tobacco's reach to improve people's health and futures. Int J Tuberc Lung Dis. 2017 05 01; 21(5):481-482. Prasad V, Fu D. PMID: 28399959.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    334. Heparin-induced thrombocytopenia: a tremendous opportunity for randomization. Blood Coagul Fibrinolysis. 2017 Apr; 28(3):272-274. Lammers A, DeLoughery T, Prasad V. PMID: 27787285.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    335. How the USPSTF's Mammographic Screening Guidelines Should Be Interpreted. Am J Med. 2017 Jul; 130(7):769-770. Prasad V. PMID: 28344145.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    336. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017 Jun; 14(6):381-390. Prasad V, De Jesús K, Mailankody S. PMID: 28290490.
      View in: PubMed   Mentions: 125     Fields:    Translation:Humans
    337. Drugs that lack single-agent activity: are they worth pursuing in combination? Nat Rev Clin Oncol. 2017 04; 14(4):193-194. Gyawali B, Prasad V. PMID: 28266519.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    338. Financial Conflicts of Interest Among Hematologist-Oncologists on Twitter. JAMA Intern Med. 2017 03 01; 177(3):425-427. Tao DL, Boothby A, McLouth J, Prasad V. PMID: 28114456.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    339. What constitutes an "unmet medical need" in oncology? An empirical evaluation of author usage in the biomedical literature. Semin Oncol. 2017 02; 44(1):8-12. Lu E, Shatzel J, Shin F, Prasad V. PMID: 28395768.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    340. The Rising Price of Cancer Drugs-A New Old Problem? JAMA Oncol. 2017 Feb 01; 3(2):277-278. Prasad V, Wang R, Afifi SH, Mailankody S. PMID: 27711927.
      View in: PubMed   Mentions: 8     Fields:    
    341. Pediatric Xanthogranulomatous Cystitis: The First Described Case in a Pre-pubertal Male and Review of the Literature. Pediatr Dev Pathol. 2017 Jul-Aug; 20(4):330-334. Preece J, Prasad V, McLeod D. PMID: 28727973.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    342. A Retrospective Cohort Study of Total Colonic Aganglionosis: Is the Appendix a Reliable Diagnostic Tool? J Neonatal Surg. 2017 Jan-Mar; 6(1):25. Reck-Burneo CA, Lane V, Vinay P, Wood R, Levitt M. PMID: 28083511; PMCID: PMC5224759.
      View in: PubMed   Mentions:
    343. Taking Care of Our Friends and Neighbors: DeVita's The Death of Cancer and the Challenge of Letting Go. JAMA Oncol. 2017 Jan 01; 3(1):16-17. Beer TM, Prasad V. PMID: 27631115.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    344. Effect of the American Society of Clinical Oncology's Conflict of Interest Policy on Information Overload. JAMA Oncol. 2016 Dec 01; 2(12):1653-1654. Boothby A, Wang R, Cetnar J, Prasad V. PMID: 27560393.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    345. Same Data; Different Interpretations. J Clin Oncol. 2016 11 01; 34(31):3729-3732. Gyawali B, Prasad V. PMID: 27573659; PMCID: PMC5477922.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    346. Industry Funding of Cancer Patient Advocacy Organizations. Mayo Clin Proc. 2016 11; 91(11):1668-1670. Abola MV, Prasad V. PMID: 27814841.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    347. Pediatric Dermatology Photoquiz: An Enlarging Facial Papule. Pediatr Dermatol. 2016 Nov; 33(6):661-662. Yanes DA, Prasad V, Fernandez Faith E. PMID: 27882660.
      View in: PubMed   Mentions:    Fields:    
    348. A Strategy for Helicobacter Immunohistochemistry Utilization in Pediatric Practice:  Insights From Morphologic and Cost-Benefit Analyses. Am J Clin Pathol. 2016 Nov 01; 146(5):611-617. Conces MR, Arnold CA, Baker PB, Carter CM, Fung B, Prasad V, Arnold MA. PMID: 28430952.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    349. Precision medicine in diffuse large B-cell lymphoma: Hype or hope? Eur J Cancer. 2016 11; 68:22-26. Prasad V. PMID: 27697586.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    350. Future jobs of FDA's haematology-oncology reviewers. BMJ. 2016 Sep 27; 354:i5055. Bien J, Prasad V. PMID: 27677772.
      View in: PubMed   Mentions: 4     Fields:    
    351. Perspective: The precision-oncology illusion. Nature. 2016 09 08; 537(7619):S63. Prasad V. PMID: 27602743.
      View in: PubMed   Mentions: 131     Fields:    Translation:Humans
    352. Negative trials in ovarian cancer: is there such a thing as too much optimism? Ecancermedicalscience. 2016; 10:ed58. Gyawali B, Prasad V. PMID: 27594913; PMCID: PMC4990052.
      View in: PubMed   Mentions: 2  
    353. Precision medicine in acute myeloid leukemia: Hope, hype or both? Leuk Res. 2016 09; 48:73-7. Prasad V, Gale RP. PMID: 27497757.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    354. Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices. JAMA. 2016 Jul 19; 316(3):271-2. Mailankody S, Prasad V. PMID: 27149663.
      View in: PubMed   Mentions: 8     Fields:    
    355. Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies. Oncologist. 2016 09; 21(9):1031-2. Mailankody S, Prasad V. PMID: 27401893; PMCID: PMC5016075.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    356. Wearables, Smartphones and Novel Anticoagulants: We Will Treat More Atrial Fibrillation, but Will Patients Be Better Off? J Gen Intern Med. 2016 11; 31(11):1367-1368. Cifu A, Prasad V. PMID: 27338593; PMCID: PMC5071280.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    357. Blood-Based Screening for Colon Cancer: A Disruptive Innovation or Simply a Disruption? JAMA. 2016 Jun 21; 315(23):2519-20. Parikh RB, Prasad V. PMID: 27305625.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    358. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable. Mayo Clin Proc. 2016 06; 91(6):707-12. Prasad V, Mailankody S. PMID: 27261866.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    359. ASCO Plenary Sessions: impact, legacy, future. Semin Oncol. 2016 06; 43(3):321-6. Vandross A, Prasad V, Mailankody S. PMID: 27178681.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    360. Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials? Med Hypotheses. 2016 Aug; 93:71-3. Prasad V. PMID: 27372859.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    361. Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. Mayo Clin Proc. 2016 May 10. Kim C, Prasad V. PMID: 27236424; PMCID: PMC5104665.
      View in: PubMed   Mentions: 35     Fields:    
    362. Spontaneous Cystic Penile Vascular Malformation in an Adolescent and Review of the Literature. Urology. 2016 Nov; 97:197-199. Preece J, Prasad V, Schober M, DaJusta DG. PMID: 27112512.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    363. Balancing Accelerated Approval for Drugs With Accelerated Withdrawal--Reply. JAMA Intern Med. 2016 Apr; 176(4):567. Kim C, Prasad V. PMID: 27043117.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    364. Characteristics and Conflicts of Public Speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration. JAMA Intern Med. 2016 Mar; 176(3):389-91. Abola MV, Prasad V. PMID: 26831527.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    365. How Should Research Be Funded? Difficulties With the Argument for Proportionality to Causes of Death or Years of Life Lost. J Natl Compr Canc Netw. 2016 Mar; 14(3):365-6. Prasad V. PMID: 26957620.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    366. Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting. Oncologist. 2016 Mar; 21(3):261-8. Massey PR, Wang R, Prasad V, Bates SE, Fojo T. PMID: 26888691; PMCID: PMC4786361.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    367. Vinay Prasad on the use of exaggerated language in cancer research, and how it can mislead doctors, patients, and the public. Oncology (Williston Park). 2016 Feb; 30(2):120-1. Prasad VK. PMID: 26888789.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    368. Precision oncology: origins, optimism, and potential. Lancet Oncol. 2016 Feb; 17(2):e81-e86. Prasad V, Fojo T, Brada M. PMID: 26868357.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCells
    369. Application of Medicare's New Technology Add-on Payment Program for Blinatumomab. JAMA Oncol. 2016 Feb; 2(2):165-6. Dhruva SS, Prasad V. PMID: 26720844.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    370. Reply to Dr. Leon: true but unrelated. J Clin Epidemiol. 2016 07; 75:127. Prasad V. PMID: 26808818.
      View in: PubMed   Mentions:    Fields:    
    371. Why cancer screening has never been shown to "save lives"--and what we can do about it. BMJ. 2016 Jan 06; 352:h6080. Prasad V, Lenzer J, Newman DH. PMID: 26740343.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    372. In Reply--Is There a Need for "Bias Police" in Industry-Sponsored Research? Mayo Clin Proc. 2016 Jan; 91(1):121. Prasad V, Berger VW. PMID: 26763516.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    373. The Use of Superlatives in Cancer Research. JAMA Oncol. 2016 Jan; 2(1):139-41. Abola MV, Prasad V. PMID: 26512913.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    374. Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer Medicine. J Glob Oncol. 2016 Feb; 2(1):1-3. Prasad V, Kumar H, Mailankody S. PMID: 28717675; PMCID: PMC5497740.
      View in: PubMed   Mentions: 4     Fields:    
    375. Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication? Eur J Heart Fail. 2016 Feb; 18(2):128-32. Vaduganathan M, Prasad V. PMID: 26663426.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    376. Translation failure and medical reversal: Two sides to the same coin. Eur J Cancer. 2016 Jan; 52:197-200. Prasad V. PMID: 26689866.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    377. Medical Debates and Medical Reversal. J Gen Intern Med. 2015 Dec; 30(12):1729-30. Cifu AS, Prasad VK. PMID: 26224155; PMCID: PMC4636561.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    378. Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5 Years of Statin Meta-Analyses. Am J Cardiovasc Drugs. 2015 Dec; 15(6):379-86. Huded C, Prasad V. PMID: 26141958.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    379. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals. JAMA Intern Med. 2015 Dec; 175(12):1992-4. Kim C, Prasad V. PMID: 26502403.
      View in: PubMed   Mentions: 122     Fields:    Translation:Humans
    380. The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary; does it also improve survival? Eur J Cancer. 2016 Feb; 54:159-162. Prasad V, Oseran A, Fakhrejahani F. PMID: 26608119.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    381. Characteristics of Exceptional or Super Responders to Cancer Drugs. Mayo Clin Proc. 2015 Dec; 90(12):1639-49. Prasad V, Vandross A. PMID: 26546106.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    382. Prostate Cancer Screening: The Pendulum has Swung, and the Burden of Proof Is with Proponents. Am Fam Physician. 2015 10 15; 92(8):678-80. Prasad V. PMID: 26554407.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    383. Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute. Oncologist. 2015 Nov; 20(11):1344-6. Mailankody S, Prasad V. PMID: 26449381; PMCID: PMC4718435.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    384. Pricing and Value of Cancer Drugs--Reply. JAMA Oncol. 2015 Sep; 1(6):842-3. Mailankody S, Prasad V. PMID: 26355867.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    385. Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis. JAMA Oncol. 2015 Sep; 1(6):787-95. Jawed I, Wilkerson J, Prasad V, Duffy AG, Fojo T. PMID: 26181239.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    386. How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses. Blood. 2015 Oct 08; 126(15):1860-1. Prasad V, Mailankody S. PMID: 26320099; PMCID: PMC4600021.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    387. Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov. Eur J Cancer. 2015 Nov; 51(17):2718-23. Prasad V, Goldstein JA. PMID: 26321010; PMCID: PMC4663106.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    388. Non-invasive, serum DNA pregnancy testing leading to incidental discovery of cancer: a good thing? Eur J Cancer. 2015 Nov; 51(16):2272-4. Prasad V. PMID: 26278647.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    389. Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start. Mayo Clin Proc. 2015 Sep; 90(9):1171-5. Prasad V, Berger VW. PMID: 26277702; PMCID: PMC4567484.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    390. The role of censoring on progression free survival: oncologist discretion advised. Eur J Cancer. 2015 Nov; 51(16):2269-71. Prasad V, Bilal U. PMID: 26259493.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    391. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. JAMA Intern Med. 2015 Aug; 175(8):1389-98. Prasad V, Kim C, Burotto M, Vandross A. PMID: 26098871.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    392. Authorship Inflation in Medical Publications. Inquiry. 2015; 52. Tilak G, Prasad V, Jena AB. PMID: 26228035; PMCID: PMC4943864.
      View in: PubMed   Mentions: 26     Fields:    
    393. Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy. J Med Genet. 2015 Sep; 52(9):627-35. Chung WK, Martin K, Jalas C, Braddock SR, Juusola J, Monaghan KG, Warner B, Franks S, Yudkoff M, Lulis L, Rhodes RH, Prasad V, Torti E, Cho MT, Shinawi M. PMID: 26185144.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    394. Optimization of CO₂ fixation by Chlorella kessleri cultivated in a closed raceway photo-bioreactor. Bioresour Technol. 2015 Oct; 194:144-55. Kasiri S, Ulrich A, Prasad V. PMID: 26188557.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    395. Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. JAMA Oncol. 2015 Jul; 1(4):539-40. Mailankody S, Prasad V. PMID: 26181265.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansPHPublic Health
    396. Response. Chest. 2015 Jul; 148(1):e31-e32. Rho J, Ho N, Prasad V. PMID: 26149564; PMCID: PMC5831562.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    397. Distinctive clinical characteristics of malignant mesothelioma in young patients. Oncotarget. 2015 Jun 30; 6(18):16766-73. Thomas A, Chen Y, Yu T, Gill A, Prasad V. PMID: 26202904; PMCID: PMC4599306.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    398. Multiplying therapies and reducing toxicity in metastatic melanoma. Cancer Biol Ther. 2015; 16(7):1014-8. Massey PR, Prasad V, Figg WD, Fojo T. PMID: 26016850; PMCID: PMC4623483.
      View in: PubMed   Mentions: 4     Fields:    
    399. Do we need randomised trials for rare cancers? Eur J Cancer. 2015 Jul; 51(11):1355-7. Prasad V, Oseran A. PMID: 25963018.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    400. Emphasizing unique strengths and eliminating redundancy for research in low-income and middle-income countries: Lessons from a South American country. Cancer. 2015 Aug 15; 121(16):2668-70. Burotto M, Prasad V. PMID: 25903222.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    401. Non-inferiority trials: why oncologists must remain wary. Lancet Oncol. 2015 Apr; 16(4):364-6. Burotto M, Prasad V, Fojo T. PMID: 25846084.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    402. In situ biodegradation of naphthenic acids in oil sands tailings pond water using indigenous algae-bacteria consortium. Bioresour Technol. 2015; 187:97-105. Mahdavi H, Prasad V, Liu Y, Ulrich AC. PMID: 25841188.
      View in: PubMed   Mentions: 7     Fields:    Translation:CellsPHPublic Health
    403. Primary chemoprevention of breast cancer: Are the adverse effects too burdensome? CMAJ. 2015 Jun 16; 187(9):E276-E278. Prasad V, Diener-West M. PMID: 25802306; PMCID: PMC4467955.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    404. Disease specific productivity of american cancer hospitals. PLoS One. 2015; 10(3):e0121233. Goldstein JA, Prasad V. PMID: 25781329; PMCID: PMC4364111.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    405. But how many people died? Health outcomes in perspective. Cleve Clin J Med. 2015 Mar; 82(3):146-50. Prasad V. PMID: 25932737.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    406. Mortality and treatment patterns among patients hospitalized with acute cardiovascular conditions during dates of national cardiology meetings. JAMA Intern Med. 2015 Feb; 175(2):237-44. Jena AB, Prasad V, Goldman DP, Romley J. PMID: 25531231; PMCID: PMC4314435.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    407. Modern drug development: which patients should come first? JAMA. 2014 Dec 24-31; 312(24):2619-20. Vaduganathan M, Prasad V. PMID: 25420013.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    408. The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab. JAMA Intern Med. 2014 Dec; 174(12):1887-8. Prasad V. PMID: 25383420.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    409. The College of American Pathologists guidelines for whole slide imaging validation are feasible for pediatric pathology: a pediatric pathology practice experience. Pediatr Dev Pathol. 2015 Mar-Apr; 18(2):109-16. Arnold MA, Chenever E, Baker PB, Boué DR, Fung B, Hammond S, Hendrickson BW, Kahwash SB, Pierson CR, Prasad V, Nicol KK, Barr T. PMID: 25387255.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    410. Primary care physicians' role in counseling about gun safety. Am Fam Physician. 2014 Nov 01; 90(9):619-20. Jena AB, Prasad V. PMID: 25368919.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    411. It is time to stop screening for prostate cancer. JAMA Intern Med. 2014 Nov; 174(11):1841-2. Prasad V. PMID: 25178980.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    412. Exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 10 02; 371(14):1358. Prasad V. PMID: 25271613.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    413. US News and World Report cancer hospital rankings: do they reflect measures of research productivity? PLoS One. 2014; 9(9):e107803. Prasad V, Goldstein JA. PMID: 25247921; PMCID: PMC4172593.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    414. Rosiglitazone, medical reversal, and back to basics for diabetes. Am Fam Physician. 2014 Sep 15; 90(6):368, 370. Prasad V. PMID: 25251229.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    415. The Peltzman effect and compensatory markers in medicine. Healthc (Amst). 2014 Sep 01; 2(3):170-172. Prasad V, Jena AB. PMID: 25396116; PMCID: PMC4226525.
      View in: PubMed   Mentions: 5     Fields:    
    416. Long-term effects of the 2003 ACGME resident duty hour reform on hospital mortality. Mayo Clin Proc. 2014 Jul; 89(7):1023-5. Jena AB, Prasad V, Romley JA. PMID: 24996240; PMCID: PMC4275102.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    417. Statins, primary prevention, and overall mortality. Ann Intern Med. 2014 Jun 17; 160(12):867-9. Prasad V. PMID: 24935491.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    418. The declining demand for hospital care as a rationale for duty hour reform. J Gen Intern Med. 2014 Oct; 29(10):1400-3. Jena AB, DePasse JW, Prasad V. PMID: 24866469; PMCID: PMC4175648.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    419. Balloon brachytherapy for breast cancer prove that it works? Or, prove that it doesn't? J Cancer Res Clin Oncol. 2014 Aug; 140(8):1353-7. Prasad V. PMID: 24858568.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    420. Rebuttal from Dr Rho et al. Chest. 2014 May; 145(5):943-4. Rho J, Ho N, Prasad V. PMID: 24798833; PMCID: PMC4011656.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    421. Counterpoint: were industry-sponsored roflumilast trials appropriate? No. Chest. 2014 May; 145(5):939-42. Rho J, Ho N, Prasad V. PMID: 24798831; PMCID: PMC4011655.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    422. The reply. Am J Med. 2014 May; 127(5):e15. Prasad V, Shea N. PMID: 24758876.
      View in: PubMed   Mentions:    Fields:    
    423. Comparative effectiveness questions in oncology. N Engl J Med. 2014 Apr 17; 370(16):1478-81. Mailankody S, Prasad V. PMID: 24738667.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    424. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol. 2014 May 20; 32(15):1620-9. Prasad V, Massey PR, Fojo T. PMID: 24711558; PMCID: PMC4026582.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    425. Why do we continue to adopt medical practices based on pathophysiology alone when we should be insisting on clinical trials? J Clin Epidemiol. 2014 Apr; 67(4):361-3. Prasad V, Ho N. PMID: 24581292.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    426. Can a resident's publication record predict fellowship publications? PLoS One. 2014; 9(3):e90140. Prasad V, Rho J, Selvaraj S, Cheung M, Vandross A, Ho N. PMID: 24658088; PMCID: PMC3962333.
      View in: PubMed   Mentions: 3     Fields:    
    427. Synovial chondromatosis of the cervical spine: a case report and review of the literature. Pediatr Dev Pathol. 2014 May-Jun; 17(3):221-5. Shaw A, Zibly Z, Prasad V, Ikeda D, Boue D, Governale LS. PMID: 24650324.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    428. Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection. Arterioscler Thromb Vasc Biol. 2014 May; 34(5):1085-92. Shaked I, Hanna DB, Gleißner C, Marsh B, Plants J, Tracy D, Anastos K, Cohen M, Golub ET, Karim R, Lazar J, Prasad V, Tien PC, Young MA, Landay AL, Kaplan RC, Ley K. PMID: 24651679; PMCID: PMC4067091.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    429. Shameful. CMAJ. 2014 Apr 01; 186(6):472. Prasad V. PMID: 24638022; PMCID: PMC3971042.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    430. Use of the Word "Cure" in the Oncology Literature. Am J Hosp Palliat Care. 2015 Aug; 32(5):477-83. Prasad V. PMID: 24558172.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    431. Aditya Jyot-Diabetic Retinopathy in Urban Mumbai Slums Study (AJ-DRUMSS): study design and methodology - report 1. Ophthalmic Epidemiol. 2014 Feb; 21(1):51-60. Sunita M, Desai S, Vinay P, Moolani S, Rai N, Deepen S, Ashwini R, Manish S, Hemangi G, Abdal O, Kulkarni P, Chakravarti A, Uthra S, Raman R, Radhika S, Natarajan S, Kumaramanickavel G, McCarty C. PMID: 24467563.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    432. Fatal extraintestinal adrenal malignancy in a 12-year-old girl with familial adenomatous polyposis. J Pediatr Gastroenterol Nutr. 2014 Feb; 58(2):e19-20. Rauch LB, Erdman SH, Aldrink JH, Ranalli MA, Prasad V, Hoffman RP. PMID: 23575299.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    433. Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design? J Cancer Res Clin Oncol. 2014 Apr; 140(4):521-4. Prasad V, Vandross A. PMID: 24474554.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    434. Does the declining lethality of gunshot injuries mask a rising epidemic of gun violence in the United States? J Gen Intern Med. 2014 Jul; 29(7):1065-9. Jena AB, Sun EC, Prasad V. PMID: 24452421; PMCID: PMC4061370.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    435. Media coverage of medical journals: do the best articles make the news? PLoS One. 2014; 9(1):e85355. Selvaraj S, Borkar DS, Prasad V. PMID: 24465543; PMCID: PMC3894978.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    436. Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices. Implement Sci. 2014 Jan 08; 9:1. Prasad V, Ioannidis JP. PMID: 24398253; PMCID: PMC3892018.
      View in: PubMed   Mentions: 134     Fields:    
    437. Regarding empiricism and rationalism in medicine and 2 medical worldviews. Mayo Clin Proc. 2014 Jan; 89(1):137. Prasad V. PMID: 24388033.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    438. Eliminating chronic kidney disease… as a diagnosis. Pol Arch Med Wewn. 2014; 124(1-2):7-9. Prasad V, Cifu A. PMID: 24531346.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    439. Comment on "Eliminating chronic kidney disease... as a diagnosis". Authors' reply. Pol Arch Med Wewn. 2014; 124(4):214. Prasad V, Cifu A. PMID: 24732318.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    440. Further thoughts on why there are good data supporting the inferior vena cava filter. JAMA Intern Med. 2014 Jan; 174(1):164-5. Prasad V, Rho J, Cifu A. PMID: 24394930.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    441. The accelerated approval of oncologic drugs: lessons from ponatinib. JAMA. 2014 Jan 22-29; 311(4):353-4. Prasad V, Mailankody S. PMID: 24449310.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansPHPublic Health
    442. The misguided ethics of crossover trials. Contemp Clin Trials. 2014 Mar; 37(2):167-9. Prasad V, Grady C. PMID: 24365533; PMCID: PMC3981898.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    443. The reversal of cardiology practices: interventions that were tried in vain. Cardiovasc Diagn Ther. 2013 Dec; 3(4):228-35. Prasad V, Cifu A. PMID: 24400206; PMCID: PMC3878120.
      View in: PubMed   Mentions:
    444. The reply. Am J Med. 2013 Dec; 126(12):e45. Shea N, Prasad V. PMID: 24262747.
      View in: PubMed   Mentions:    Fields:    
    445. Dense breasts and legislating medicine. Cleve Clin J Med. 2013 Dec; 80(12):768-70. Ho N, Kim J, Prasad V. PMID: 24307160.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    446. The reply. Am J Med. 2014 Mar; 127(3):e21. Prasad V, Kim J, Rho J. PMID: 24291600.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    447. Firearm legislation and gun-related fatalities. JAMA Intern Med. 2013 Nov 25; 173(21):2011. Jena AB, Sun EC, Prasad V. PMID: 24276051.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    448. Persistent reservations against the premedical and medical curriculum. Perspect Med Educ. 2013 Nov; 2(5-6):335-339. Prasad V. PMID: 23670684; PMCID: PMC3824759.
      View in: PubMed   Mentions: 1     Fields:    
    449. Observational studies cannot justify the inferior vena cava filter. Am J Med. 2014 Mar; 127(3):e15. Prasad V. PMID: 24560327.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    450. The inferior vena cava filter--reply. JAMA Intern Med. 2013 Oct 14; 173(18):1754-5. Prasad V, Rho J, Cifu A. PMID: 24126777.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    451. Powering cancer screening for overall mortality. Ecancermedicalscience. 2013; 7:ed27. Prasad V. PMID: 24883096; PMCID: PMC4025495.
      View in: PubMed   Mentions:
    452. Why randomized controlled trials are needed to accept new practices: 2 medical worldviews. Mayo Clin Proc. 2013 Oct; 88(10):1046-50. Prasad V. PMID: 24079676.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    453. The overdiagnosis of pneumonia. Cleve Clin J Med. 2013 Oct; 80(10):616-8. Prasad V. PMID: 24085804.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    454. In reply I-reversal of medical practices. Mayo Clin Proc. 2013 Oct; 88(10):1183-4. Prasad V, Cifu A. PMID: 24079692.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    455. Utility of tissue transglutaminase immunohistochemistry in pediatric duodenal biopsies: patterns of expression and role in celiac disease-a clinicopathologic review. Patholog Res Int. 2013; 2013:602985. Almarzooqi S, Houston RH, Prasad V. PMID: 24195009; PMCID: PMC3782127.
      View in: PubMed   Mentions:
    456. Xanthogranulomatous appendicitis in a child: report of a case and review of the literature. Case Rep Med. 2013; 2013:498191. Al-Rawabdeh SM, Prasad V, King DR, Kahwash SB. PMID: 24093025; PMCID: PMC3777195.
      View in: PubMed   Mentions: 9  
    457. Why resident physicians stay late. CMAJ. 2013 Sep 17; 185(13):1184. Prasad V. PMID: 24003103; PMCID: PMC3778495.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    458. Duty hour reform in a shifting medical landscape. J Gen Intern Med. 2013 Sep; 28(9):1238-40. Jena AB, Prasad V. PMID: 23568191; PMCID: PMC3744286.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    459. Osmotic virial coefficients of hydroxyethyl starch from aqueous hydroxyethyl starch-sodium chloride vapor pressure osmometry. J Phys Chem B. 2013 Sep 05; 117(35):10231-40. Cheng J, Gier M, Ross-Rodriguez LU, Prasad V, Elliott JA, Sputtek A. PMID: 23862979.
      View in: PubMed   Mentions:    Fields:    
    460. Handheld ultrasounds: pocket sized, but pocket ready? Am J Med. 2013 Oct; 126(10):845-6. Kim JK, Rho J, Prasad V. PMID: 23910521.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    461. Evaluating health system processes with randomized controlled trials. JAMA Intern Med. 2013 Jul 22; 173(14):1279-80. Ioannidis JP, Prasad V. PMID: 23689271.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    462. Taking care of sick patients. CMAJ. 2013 Aug 06; 185(11):1008. Prasad V. PMID: 23877668; PMCID: PMC3735754.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    463. A decade of reversal: an analysis of 146 contradicted medical practices. Mayo Clin Proc. 2013 Aug; 88(8):790-8. Prasad V, Vandross A, Toomey C, Cheung M, Rho J, Quinn S, Chacko SJ, Borkar D, Gall V, Selvaraj S, Ho N, Cifu A. PMID: 23871230.
      View in: PubMed   Mentions: 105     Fields:    Translation:Humans
    464. Treatment of moderate to severe hidradenitis suppurativa. Ann Intern Med. 2013 Jul 02; 159(1):72. Prasad V. PMID: 23817709.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    465. Open issues with open access publication. Am J Med. 2013 Jul; 126(7):563-4. Shea N, Prasad V. PMID: 23787194.
      View in: PubMed   Mentions: 5     Fields:    
    466. Routine noninvasive testing and highly sensitive troponin immunoassays--reply. JAMA Intern Med. 2013 May 13; 173(9):833-4. Prasad V, Cheung M, Cifu A. PMID: 23700018.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    467. Subclavian vein aneurysm secondary to a benign vessel wall hamartoma. Pediatr Radiol. 2013 Nov; 43(11):1528-31. Warren P, Spaeth M, Prasad V, McConnell P. PMID: 23636539.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    468. Falsification end points for observational studies--reply. JAMA. 2013 May 01; 309(17):1770-1. Jena AB, Prasad V. PMID: 23632713.
      View in: PubMed   Mentions: 1     Fields:    
    469. Double-crossed: why crossover in clinical trials may be distorting medical science. J Natl Compr Canc Netw. 2013 May 01; 11(5):625-7. Prasad V. PMID: 23667211.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    470. The inferior vena cava filter: how could a medical device be so well accepted without any evidence of efficacy? JAMA Intern Med. 2013 Apr 08; 173(7):493-5; discussion 495. Prasad V, Rho J, Cifu A. PMID: 23552611.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    471. Characteristics of cluster randomized trials: are they living up to the randomized trial? JAMA Intern Med. 2013 Feb 25; 173(4):313-5. Selvaraj S, Prasad V. PMID: 23337957.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    472. Observational studies often make clinical practice recommendations: an empirical evaluation of authors' attitudes. J Clin Epidemiol. 2013 Apr; 66(4):361-366.e4. Prasad V, Jorgenson J, Ioannidis JP, Cifu A. PMID: 23384591.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    473. Prespecified falsification end points: can they validate true observational associations? JAMA. 2013 Jan 16; 309(3):241-2. Prasad V, Jena AB. PMID: 23321761.
      View in: PubMed   Mentions: 99     Fields:    
    474. Probiotics, prebiotics, synbiotics and naturally fermented foods: why more may be more. Ann Gastroenterol. 2013; 26(3):277-278. Ho N, Prasad V. PMID: 24714309; PMCID: PMC3959447.
      View in: PubMed   Mentions: 2  
    475. When research evidence is misleading. Virtual Mentor. 2013 Jan 01; 15(1):29-33. Huded C, Rosno J, Prasad V. PMID: 23356804.
      View in: PubMed   Mentions:    Fields:    
    476. Couple therapy for posttraumatic stress disorder. JAMA. 2012 Dec 19; 308(23):2458; author reply 2458. Prasad V. PMID: 23288147.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    477. Holiday reading: The facts are the facts. CMAJ. 2012 Dec 11; 184(18):2029-30. Prasad V. PMID: 23230055; PMCID: PMC3519195.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    478. Freedom to innovate: the perils of centralized medical research-reply. Arch Intern Med. 2012 Nov 26; 172(21):1692-3. Prasad V, Rho J, Cifu A. PMID: 23753119.
      View in: PubMed   Mentions:    Fields:    
    479. Chest pain in the emergency department: the case against our current practice of routine noninvasive testing. Arch Intern Med. 2012 Oct 22; 172(19):1506-9. Prasad V, Cheung M, Cifu A. PMID: 22987111.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    480. An unmeasured harm of screening. Arch Intern Med. 2012 Oct 22; 172(19):1442-3. Prasad V. PMID: 22987011.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    481. Raise the bar even higher for primary prevention interventions-reply. Arch Intern Med. 2012 Sep 24; 172(17):1352-3. Prasad V, Vandross A. PMID: 23752665.
      View in: PubMed   Mentions:    Fields:    
    482. The conundrum of cost-effectiveness. Cleve Clin J Med. 2012 Sep; 79(9):610-1. Prasad V. PMID: 22949341.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    483. Publication trends among internal medicine residents and graduates. Am J Med. 2012 Sep; 125(9):939-44. Prasad V, Rho J, Selvaraj S, Toomey C, Vandross A, Ho N. PMID: 22938929.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    484. The diagnosis and treatment of pulmonary embolism: a metaphor for medicine in the evidence-based medicine era. Arch Intern Med. 2012 Jun 25; 172(12):955-8. Prasad V, Rho J, Cifu A. PMID: 22473672.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    485. The apples and oranges of cost-effectiveness. Cleve Clin J Med. 2012 Jun; 79(6):377-9. Prasad V. PMID: 22660868.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    486. Cardiovascular primary prevention: how high should we set the bar? Arch Intern Med. 2012 Apr 23; 172(8):656-9; discussion 659. Prasad V, Vandross A. PMID: 22529231.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    487. New frontiers for stroke prevention in atrial fibrillation. Cerebrovasc Dis. 2012; 33(3):199-208. Prasad V, Kaplan RM, Passman RS. PMID: 22261539.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    488. Reversals of established medical practices: evidence to abandon ship. JAMA. 2012 Jan 04; 307(1):37-8. Prasad V, Cifu A, Ioannidis JP. PMID: 22215160.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansPHPublic Health
    489. Medical reversal: why we must raise the bar before adopting new technologies. Yale J Biol Med. 2011 Dec; 84(4):471-8. Prasad V, Cifu A. PMID: 22180684; PMCID: PMC3238324.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    490. Selective therapeutic hypothermia: a review of invasive and noninvasive techniques. Arq Neuropsiquiatr. 2011 Dec; 69(6):981-7. Straus D, Prasad V, Munoz L. PMID: 22297891.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    491. The cardiovascular biomarker conundrum: challenges and solutions. JAMA. 2011 Nov 16; 306(19):2151-2. Prasad V, Bonow RO. PMID: 22089725.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    492. Are we treating professionalism professionally? Medical school behavior as predictors of future outcomes. Teach Learn Med. 2011 Oct; 23(4):337-41. Prasad V. PMID: 22004318.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    493. Clostridium difficile diarrhea and fecal transplantation. J Clin Gastroenterol. 2011 Sep; 45(8):742-3. Ho N, Prasad V. PMID: 21555950.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    494. The frequency of medical reversal. Arch Intern Med. 2011 Oct 10; 171(18):1675-6. Prasad V, Gall V, Cifu A. PMID: 21747003.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    495. Effect of clinical vignettes on senior medical students' opinions of climate change. South Med J. 2011 Jun; 104(6):401-4. Prasad V, Thistlethwaite W, Dale W. PMID: 21886028.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    496. Lacking the incentive to cure? Recurring Clostridium difficile diarrhea and our reluctance to use fecal transplantation. J Clin Gastroenterol. 2011 Apr; 45(4):379-80. Ho N, Prasad V. PMID: 21278582.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    497. Steroids in infection: an old wives' tale. CMAJ. 2011 Jan 11; 183(1):83; author reply 83-4. Prasad V. PMID: 21220464; PMCID: PMC3017262.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    498. Caution needed when predicting problem residents. Acad Med. 2011 Jan; 86(1):2; author reply 2. Prasad V. PMID: 21191193.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    499. Holiday reading: A la carte medicine. CMAJ. 2010 Dec 14; 182(18):2011-2. Prasad V. PMID: 21149538; PMCID: PMC3001514.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    500. Baseline event rate, the Concorde fallacy, and the topography of cardiac risk. Med Hypotheses. 2010 Dec; 75(6):639-41. Prasad V. PMID: 20800366.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    501. Language in the end. Explaining the death of a loved one. J Gen Intern Med. 2010 Aug; 25(8):884-5. Prasad V. PMID: 20443071; PMCID: PMC2896594.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    502. Reclaiming the morbidity and mortality conference: between Codman and Kundera. Med Humanit. 2010 Dec; 36(2):108-11. Prasad V. PMID: 21393293.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    503. Perspective: beyond storytelling in medicine: an encounter-based curriculum. Acad Med. 2010 May; 85(5):794-8. Prasad V. PMID: 20520028.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    504. Toward a meaningful alternative medicine. Hastings Cent Rep. 2009 Sep-Oct; 39(5):16-8. Prasad V. PMID: 19806774.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    Vinayak's Networks